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KATELYNN AMBER TOOMER, Primary Cilia in Cardiac Valve Development and
Disease (Under the direction of RUSSELL A. NORRIS)
ABSTRACT
Cardiac valve disease is a major health burden affecting around 5% of the population.
Two of the most common cardiac valve disease include mitral valve prolapse (MVP) and
bicuspid aortic valve disease (BAV). Currently treatment options consist of invasive
surgeries to either repair or replace the damages valve tissues. Evidence suggests that
both MVP and BAV are congenital diseases that present complications in patients later in
life. Treatment options for these diseases are lacking due to an incomplete understanding
of the molecular causes.
Mitral valve prolapse (MVP) is one of the most common forms of cardiac valve
disease and affects ~2-3% of the human population. MVP can lead to secondary
complications such as arrhythmias, heart failure, and sudden cardiac death and 1 in 10
patients will require valve surgery. There are no effective nonsurgical treatments for
MVP and therapeutic efforts have been hindered by an incomplete understanding of its
fundamental causes. One accessible source of such information may come from genetic
studies of MVP. We previously reported familial and GWAS studies that identified
genetic mutations and/or excellent candidate targets as causal to MVP. Pathway analyses
suggested a common cellular and molecular thread between these studies and invoke the
primary cilia as potential unifying mechanism. This discovery is further bolstered by our
recent identification of a mutation in a cilia gene in a large family with MVP, DZIP1.
Our data show genetic haploinsufficiency of primary cilia in cardiac valves leads to a
non-syndromic mitral valve disease in mouse models whereas complete genetic ablation
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enhances mitral valve phenotype severity and generation of bicuspid aortic valve (BAV).
We present, for the first time, a potential common cellular and molecular thread through
which MVP and potentially BAV can arise. These studies define the primary cilia as a
critical, and previously unrecognized facet of cardiac valve development. Uncovering
how valve disease genes regulate downstream signaling cascades will provide key
mechanistic insights into MVP and potentially BAV pathogenesis at a cellular and
molecular level.

xii

CHAPTER 1: INTRODUCTION
In the United States it is estimated that 92.1 million adults have at least one type of
cardiovascular disease, a number that is projected to grow to around 140 million US
adults in 2030 (Benjamin, Blaha et al. 2017). One of the most common cardiac diseases
in today’s society is heart valve disease with a prevalence of about 5%, causing over
24,000 deaths each year in the United States with no effective non-surgical treatment
(Benjamin, Blaha et al. 2017). Heart valve disease can either be acquired or congenital
and shows variable expression and severity. Thus, depending on the type of valve
disease, heterogeneity and variability in age of clinical presentation is the rule versus the
exception. In addition to heart valve disease being a major cause of morbidity and
mortality in the aged population, congenital or developmental defects in the
cardiovascular system are the most common cause of infant deaths. How these defects
occur, the mechanisms that result in the disease progression, and potential treatments
options are poorly understood. The overall goal of my research throughout the past 5
years was to take genetic information from patients with common cardiac valve diseases
and elucidate the reason that valve diseases occur. Our studies have led to the uncovering
of new molecular and cellular mechanisms during valve development. The following
chapters will detail how we identified mechanisms underlying valve development and
disease, the specific types of valve diseases we studied, and potential to harness this
information for new treatments beneficial to patients with valve diseases.

Cardiac Valves:
The mammalian heart is composed of four chambers: 2 atria and 2 ventricles.
Controlling unidirectional blood flow from the atria into the ventricles and out through
the arterial connections are the cardiac valves (Fig 1.1). The atrioventricular mitral and
tricuspid valves are positioned at the intersection between the left atrium/ventricle and the
right atrium/ventricle, respectively. These sets of valves are critical for regulating proper
blood flow that enters the heart and passes through the atria to the ventricles and are thus
called “in-flow” valves. During ventricular contraction, these valves shut and blood exits
through outlet segments. Blood from the left ventricle exits through the aortic valves,
into the aorta and serves to feed the body. The deoxygenated blood subsequently returns
to the right side of the heart and, upon right ventricular contraction, is pumped out
through the pulmonic valves and into the pulmonary arteries on its way to the lungs (Fig
1.1). Oxygenated blood returns to the left side of the heart, and the cycle continues for
the duration of life. Defects in the function of any of these valves results in changes in
the proper cycling of blood and can lead to serious health complications and death. Thus,
understanding how valve defects occur is critical for improving patient health. Defining
how valves form during development will likely provide key insight into how their
dysfunction occurs, with the hypothesis that altered construction of these tissues will
engender life-long defects that effect morbidity and mortality.
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Figure 1.1 The Human Heart. Sketch showing the inside of a human heart. Oxygenated blood flows
into the left atria from the lungs and travels through the mitral valve into the left ventricle. During
contraction blood then moves through the aortic valves into the aorta and to the rest of the body. Deoxygenated blood enters the heart through the superior vena cava into the right atrium through the
tricuspid valve and into the right ventricle. De-oxygenated blood then leaves the heart traveling
through the pulmonary valve and out the pulmonary artery to the lungs. Drawing by Rebecca Stairley.
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The Developmental Origin of Cardiac Valves:
During development the heart valves form from rudimentary structures called
“endocardial cushions”. The outflow tract cushions develop into aortic and pulmonary
valves (cusps) while the atrioventricular (inflow) cushions develop into mitral and
tricuspid valves (leaflets). Orchestration of how these cushions form and mature into
valve leaflets or cusps is complex and requires the integration of biomechanical stimuli,
extracellular signals, intracellular signaling cascades and transcriptional regulation of
target genes, all occurring in the heart which is continually beating. Alterations in any
steps of the developmental process are known to cause defects in valve formation. Based
on these previous studies, many valve diseases are known to have a developmental origin
and underscore the importance of defining how the integration of molecular, mechanical
and biochemical cues provide a road-map for valve development.
The structure and function of the valves are dependent on how they are built
during development. Cardiac valve development occurs in multiple stages; formation of
the cardiac jelly, migration of endocardial cells into the cardiac jelly, proliferation and
matrix deposition of post endothelial to mesenchymal transformation (EMT) cells, matrix
compaction and elongation and stratification of valve matrix into distinct layers. Cardiac
development begins with the migration of two populations of cells from the primitive
streak, forming the primary and secondary heart fields. Around E8.0 in mouse, these two
cell populations fuse to form the cardiac crescent (Combs and Yutzey 2009, Garside,
Chang et al. 2013). The primary heart field cells give rise to the left ventricle,
atrioventricular canal, and part of the right ventricle and atria while the second heart field
contributes to the right ventricle, atria outflow tract, and interventricular septum. Around
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E8.5, the cardiac crescent fuses, thereby generating a linear heart tube. The heart tube
consists of an outer myocardial layer and inner endocardial layer which are separated by
a layer of extracellular matrix called the cardiac jelly composed mostly of proteoglycan
glycosaminoglycans. This tube loops rightward to form the four-chambered mammalian
heart. After looping to the right, the heart tube forms specified structures such as the
atrioventricular (AV) junction and ventricular outflow tract (OFT). At this stage,
myocardial cells begin secreting ECM. The initial stages of valvulogenesis begin with the
formation of the atrioventricular (AV) and outflow tract cushions (OFT). The mural
leaflets of the AV valve form through the formation of lateral cushions on the left and
right side of the AV junction (Wessels, Markman et al. 1996). The superior and inferior
endocardial cushions fuse together to form components of the AV septum which later
fuses with the developing ventricular septum, mesenchymal cap and dorsal mesenchymal
protrusion (DMP). Together these different structures form the valvuloseptal complex
(Perez-Pomares, Phelps et al. 2002). This structure forms the anterior leaflet of the mitral
valve and septal leaflet of the tricuspid valve.
The cardiac cushions form when myocardium secretes ECM, called cardiac jelly,
into the interstitial space between the endocardium and myocardium. This matrix is
composed of collagens (I, III, IV), glycoproteins (fibronectin, laminin, fibrillin), and
mucopolysaccharides (glycosaminoglycans like chondroitin sulfate and hyaluranate)
(Manasek 1970).

As the cushion matures (E9.5-10.5), endocardial cells undergo

endothelial to mesenchymal transformation (EMT) and migrate into the cardiac jelly
(Markwald, Fitzharris et al. 1977). In order for cells to undergo this process, they must
lose cell-cell junctions, cell polarity, transition into mesenchymal cells, and acquire a
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migratory phenotype (Garside, Chang et al. 2013). Pioneering work by Markwald and
Bernake in 1982 showed that a subset of endocardial cells from explanted AV canals,
isolated prior to EMT were capable of transforming into mesenchymal cells with
invasive, migratory potential (Bernanke and Markwald 1982). They, and others, also
showed that this process is dependent on signals from the myocardium (Runyan and
Markwald 1983, Mjaatvedt, Lepera et al. 1987).
Two major players in this EMT process are TGFβ and BMP. These signals are
important for embryonic development as deletion of either TGFβ or BMP result in
embryonic lethality. In early cushion formation, BMP is required for the activation of the
endocardium, formation of the cardiac jelly, and for initiation and formation of the
cushions. BMP2 secreted by the myocardium is necessary for AV valve EMT while
BMP4 is necessary for OFT cushion growth. Deletion of BMP2 specifically from the
myocardium using Nkx2.5-Cre results in failure of cushion formation (Ma, Lu et al.
2005). Mice lacking the BMP receptor ALK2 fail to transform into mesenchymal cells
and result in embryonic lethality(Wang, Sridurongrit et al. 2005).
TGFβ also plays a critical role in the EMT process through promotion of
mesenchymal invasiveness (MacGrogan, Luxan et al. 2014, Bosada, Devasthali et al.
2016). TGFβ 1 and 2 are expressed during early cushion formation in the cardiac
cushion mesenchyme and by the endocardium prior to invasion. TGFβ3 however is
expressed after EMT and is not expressed in the endocardium suggesting its role may be
in the later remodeling phase of valve development. Experiments show TGFβ is
sufficient to induce EMT in chick explants. Treatment of explants with TGFβ1 induces
EMT in the absence of the normally required AV myocardium (Potts and Runyan 1989,
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Ramsdell and Markwald 1997). Additionally, neutralizing antibodies for TGFβ1 or
TGFβ3 prevent the formation and migration of cushion mesenchymal cells.
After receiving signals from the myocardium, endocardial cells then have to
disconnect from each other in order to migrate into the cardiac jelly. Notch1 signaling
during this time is important for cells undergoing EMT to delaminate from the
endocardial layer. In Notch signaling mutants, cells fail to delaminate and migrate into
the ECM. It is thought that Notch signaling induces expression of pro-migratory
transcription factor Snail which directly represses VE-cadherin promoter activity (Combs
and Yutzey 2009). Loss of endocardial cell-cell adhesion during EMT is associated with
down regulation of VE-cadherin as well as neural cell adhesion molecule (N-CAM),
vascular endothelial (VE)-cadherin, and platelet endothelial cell adhesion molecule 1
(PECAM-1)(Crossin 1991, Baldwin, Shen et al. 1994).
In addition to cells undergoing EMT a subpopulation of endothelial cells remain
lining the cushion where they are necessary in forming a tight protective boarder. The
endocardial transcription factor, nuclear factor of activated T cells-c1 (Nfatc1), is
important in maintaining endothelial phenotype and promoting proliferation of
endothelial cells which do not undergo the EMT process (Sugi, Yamamura et al. 2004,
Wu, Wang et al. 2011, MacGrogan, Luxan et al. 2014, Bosada, Devasthali et al. 2016,
Saxon, Baer et al. 2017).These endothelial cells do not undergo EMT and are maintained
as the boundary of cushion development.
After migrating into the cardiac jelly, EMT derived cells undergo a highly
proliferative stage in order to populate the forming tissue. Fibroblast growth factor
(FGFs) promote post-EMT mesenchymal cell proliferation. Treatment of chick
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atrioventricular valve cushion (AVC) explants with FGF results in increased cell
proliferation (Sugi, Ito et al. 2003). Epidermal growth factor (EGF), however, has the
opposite effect. EGF inhibits BMP signaling which is necessary for activation of
SMAD1/5/8. Studies have shown mutations causing reduction in EGF signaling result in
increased cell proliferation through activation of BMP (Person, Klewer et al. 2005).
Mesenchymal cells during this stage in valve development express twist1, Msx1/2, Sox9
and Tbx20, factors that have been shown to be important for promoting proliferation (de
Vlaming, Sauls et al. 2012).
Around E14.5 many cell processes are occurring including cell migration and
ECM secretion and remodeling. Cells adopt a fibroblast-like phenotype where they
produce fibrillar collagens and become contractile, breaking down and synthesizing
matrix. These cells then express alpha smooth muscle actin (aSMA) a marker of activated
fibroblasts. These processes are less well defined although some progress has recently
been made. During this stage in development, ECM compartments form and ultimately
results in the beginning of zonal boundaries demarcated by areas of collagen and
proteoglycan secretion. Additionally, between E14.5 and E18.5 cell density increases
with condensation occurring first at the atrial side and expanding towards the ventricular
side (Kruithof, Krawitz et al. 2007). Valvular interstitial cells increase expression of Ncadherin, proliferating cell nuclear antigen (PCNA) and αSMA. N-cadherin promotes
cell adhesion and is necessary for cell alignment and leaflet elongation. Improper
alignment of cells within the leaflet results in disorganized matrix production and
ultimately valve disease. At this stage cell polarity is important in order to begin properly
aligning cells within the tissue.
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Deposition and remodeling of matrix through compaction is also occurring at
these later stages of valve development (E17.5-postnatal stages) as indicated by increase
αSMA and BMP expression (Kruithof, Krawitz et al. 2007). BMP, periostin, and Nfatc1
play important roles in this remodeling process. BMP is important in this stage of
development as well because it regulates expression of Tbx2. Mice lacking BMP2
expression fail to express Tbx2 which is necessary for increased ECM deposition (Combs
and Yutzey 2009). Periostin, a matricellular protein involved in connecting cell surface
to structural ECM components, is also highly expressed. Studies have shown that
periostin plays an important role in compaction of the cushion mesenchyme and is
important for valve development (Ghatak, Misra et al. 2014). Loss of periostin results in
a non-compacted myxomatous-like phenotype (Norris, Borg et al. 2008).
Filamin-A (FLNA) is also very important for the remodeling stages of valve
development. FLNA is a cytoskeletal actin-binding protein that when removed causes
cardiac valvular dystrophy. Functionally, FLNA cross-links cortical actin filaments into
three dimensional structures. Knockout mice have defects in post-EMT cardiac
morphogenesis suggesting its role in valve remodeling. Other proteins expressed in the
valve during this remodeling phase of development include the small GTPases Rho and
Rac. These proteins function to interact with the actin cytoskeleton in order to compact
the ECM.
Mesenchymal cells stop expressing Twist1, Tbx20, Msx1, and Msx2 and begin to
express markers of more differentiated lineages (Tao, Kotick et al. 2012). Interestingly,
these markers often are similar to those found in cartilage and early bone formation
(Combs and Yutzey 2009). Condensation of matrix in skeletal development is necessary
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for patterning of condensed areas into bone. For this reason, expression of these markers
in valve development might be required for ECM patterning into specified matrix
regions. In the condensing late embryonic valves, BMP2 signals activate Sox9
transcription factor and expression of aggrecan. In addition, FGF4 activates scleraxis and
tenascin, genes that are characteristic of the collagen rich fibrosa layer of the valve.
The valves continue to develop during late gestation and into postnatal times
changing to accommodate different hemodynamic forces and molecular signals. Cells in
postnatal valve leaflets continue to remodel matrix and begin the elongation phase where
proliferation within specified regions and apoptosis in other regions occurs. This is
necessary in order to regulate valve growth to form a thin elongated valve. Molecular
signals from FGF4 stimulates proliferation in the distal tip, while EGF and TGFβ 2
prevent proliferation at the base of the developing valve (Sugi, Ito et al. 2003, Butcher
and Markwald 2007).
Finally, the valve undergoes ECM stratification and development of distinct
spongiosa and fibrosa regions composed of mainly collagens and proteoglycans,
respectively (Riem Vis, Kluin et al. 2011). Elastin expression is localized to the flow side
of the valve while collagens are expressed in the fibrosa layer away from blood
flow(Hinton and Yutzey 2011).

The developmental and molecular mechanisms

regulating valve stratification are currently not known.

Valve Cells Types
The postnatal valve is composed of valvular interstitial cells (VIC), which
constitute the majority of the valve and are typically fibroblastic, and valvular endothelial
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cells (VEC) which cover the valve and provide a tight outer boarder. VICs are believed to
have many different characteristics depending on their location within the tissue. In fact,
some people believe there are at least 5-10 different phenotypes of a valve interstitial cell
(Liu, Joag et al. 2007, Horne, VandeKopple et al. 2015). These cells can range in
phenotype from matrix remodeling activated fibroblast that express aSMA to dormant
VICs that populate the leaflets. VECs are critical for maintaining homeostasis in the
valve through regulations of inflammation and vascular remodeling(Butcher and Nerem
2007). Disruption of the endothelial boarder has been shown to lead to valve disease
(Leask, Jain et al. 2003, Butcher and Markwald 2007, El-Hamamsy, Balachandran et al.
2009). During disease, VECs have been shown to undergo EMT and repopulate the valve
(Bischoff and Aikawa 2011).
VICs are the cells that populate the valve and are responsible for matrix
deposition and maintenance of the tri-layer ECM structure. They have great plasticity and
can change back and forth between fibroblasts and smooth muscle cells secreting both
matrix and matrix metalloproteases (MMPs). In healthy valves VICs are primarily
quiescent however in disease they become activated and can become contractile and
migratory(Rabkin-Aikawa, Farber et al. 2004). VICs can respond to biochemical and
biomechanical stresses.

For example, ex-vivo stretching can alter transcriptional

responses and lead to increased expression of inflammatory genes. (Warnock, Nanduri et
al. 2011). In addition, in experiments when valves are removed and placed under planar
tension they up-regulate expression of α-smooth muscle actin. This leads to remodeling
of ECM components through activation of RhoA (Gould, Yalcin et al. 2016).
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Valve endothelial cells (VECs) also play an important role in valve biology.
VECs are responsible for serving as a boundary between VICs and the hemodynamic
environment of the heart. Since VECs are in contact with the circulation, they are
exposed to shear stress and circulating signaling molecules, cytokines and other risk
factors such as cholesterol, lipids and inflammatory cells (Huk, Austin et al. 2016). In this
way VECs can also signal to underlying VICs to influence behavior and ECM
production. Studies have shown that TGFb1 expressed by VECs can induce expression of
Sox9 in developing VICs (Huk, Austin et al. 2016). In aortic valves, it has been shown
that the VECs play a role in VIC response to stress, again demonstrating the importance
of a proper endothelial border (Butcher and Nerem 2006).
An additional cell type that is sometimes found in the valve are hematopoietic
derived cells. This cell type is less well described and are thought to be derived from
either infiltrating circulating cells or activation of osteoblastic phenotypes in resident
VICs(Liu, Joag et al. 2007, Huk, Austin et al. 2016). In normal tissue and disease,
circulating immune cells positive for CD45, infiltrate the valve tissue and have the ability
to remodel matrix (Barth, Koster et al. 2005, Hajdu, Romeo et al. 2011). Our group has
shown that in both humans and mice with myxomatous valve disease there is an increase
in hematopoietic cell engraftment (Sauls, Toomer et al. 2015). Localization of these cells,
in disease states, correlates with increased MMP2 expression suggesting that these cells
are promoting myxomatous degeneration through a paracrine mechanism with resident
VICs.
Although a large majority of the processes during valve development are the same
among the different valves, there are some molecular and hemodynamic differences. A
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major difference between AV and OFT development is the contribution of different cell
types and biomechanical forces. The consequences of these differences are not fully
appreciated but are believed to contribute to the unique tissue-specific anatomical
functions of each valve tissue.

Outlet Valves
The semilunar valves develop from two distinct cell populations, endocardial cells
that undergo EMT and contribute to the proximal cushions, and neural crest cells (NCCs)
that migrate to the distal cushions from the dorsal neural tube (Kelly, Brown et al. 2001).
Early in development, NCCs from the aortic arch migrate to the developing cushion. At
the same time, a subpopulation of cells undergo EMT and invade the cushions. Fusion of
these two cell populations is essential for the formation of the aortic and pulmonic
outlets. Shortly after the cushions are formed the intermediate part of the outflow tract
splits into the aorta and the pulmonary trunk. This process is facilitated by migration of
cells from the second heart field and fusion of two different populations of neural crest
cells (Spicer, Bridgeman et al. 2014).

Inlet Valves
In addition to endocardially derived cells, the AV valves are also composed of
epicardially derived cells (EPDCs). Epicardial cells expressing WT1 migrate into mainly
the mural leaflets but also the septal leaflets beginning around E12 (Wessels, van den
Hoff et al. 2012). As the valves continue to develop, between E12 and postnatal day 0,
more of the leaflets are populated with EPDCs. In the mural leaflets, which are largely
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derived from the lateral atrioventricular cushions, the EPDCs replace a significant
amount of endocardially derived cells whereas the septal leaflets have very few EPDCs
as a contributing cell population (Wessels, van den Hoff et al. 2012). This process is
regulated, in part, by signaling of Bmp2 through its receptor Alk3. Loss of Alk3 in
EPDCs results in loss of EPDC migration into the mural or posterior AV valve leading.
Loss of this signaling pathway leads to enlarged valves during development and
myxomatous valves in adult mice(Lockhart, Boukens et al. 2014).

Biomechanical Influences
Biomechanical forces are also a differing factor in the development of AV and
OFT valves. It is well established that hemodynamics play a significant role in the
development of the cardiac tissues. In the mature heart, blood flows from areas of low
pressure regions such as the atria to those of high pressure regions in the ventricles. For
this reason, the AV valves experience different pressures than the OFT valves. Studies
have shown that the mechanical forces of the beating heart during development influence
the formation and matrix composition of the valves (Butcher, McQuinn et al. 2007).
Matrix within the valves is organized within specific regions based, at least partly, on the
hemodynamic forces the valves are exposed to. In addition, the leaflet shape and
constrains felt by the AV and OFT valves are different. In the mitral valve, the leaflets
are connected to tendinous chords, which attach to the left ventricular myocardium via
the papillary muscle. These fibrous structures provide tension to the mitral leaflets on a
beat-by-beat basis and keep the tissues from billowing back into the left atrium. The
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outflow tract cusps, alternatively, do not have chordal structures and attach directly to the
wall of the aorta.
A study looking at postnatal valve remodeling showed that mitral valve leaflets
and aortic cusps behaved differently in response to biomechanical forces. Mitral valve
leaflets that underwent sustained increase in systolic load undergo significant lengthening
compared to controls while there was no change in aortic valve annulus (Tibayan, Louey
et al. 2015). The authors speculated that this change was caused by differences in the
support systems of the different valves allowing the aortic valve to be resistant to loadinduced dilation. While dilation of the aortic annulus doesn’t change in response to
biomechanical load, studies have shown that constriction of OFT during chick
development results in decreased OFT cushion volume and altered gene expression in the
cushions (Menon, Eberth et al. 2015, Menon, Eberth et al. 2017).

Parallels Between Valve and Limb Development
A parallel can be drawn between cardiac cushion development and limb bud
development. Similar developmental processes occur in each tissue. Expression of
cartilage, tendon, and bone are important for heart valve maturation and ECM
remodeling. During disease development ECM boundaries are lost resulting in defects in
mechanical function of the valve. Often, heart valve disease such as Marfans, EhlersDanlos, and Stickler syndrome, occur because manifestation of connective tissue
disorders that affect cartilage, tendon, bone and skin (Lincoln, Lange et al. 2006).
Protein expression during limb and valve development are also very similar.
Sox9, BMP2, and aggrecan, for example, are all important for differentiation and
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remodeling in both tissues. In the developing limb bud BMP induces expression of Sox9
and aggrecan which are necessary for differentiation of chondrocytes into bone
(Akiyama, Chaboissier et al. 2002). This pathway is also expressed during valve
development. BMP2 is highly expressed by the developing cushion tissue where it also
induces Sox9 and aggrecan expression (Lincoln, Kist et al. 2007). Sox9 during late
embryonic valve development is necessary for proper valve remodeling.
Signaling mechanisms between the two tissues seems to also be conserved. In the
limb bud, distinct zonal boundaries are defined by secreted signals in those locations, one
of which is hedgehog signaling. In the valve, these regions coincide with differential gene
expression of proteins such as collagens and proteoglycans. Currently the molecular cues
that cause zonal boundaries and cellular phenotypic changes during valvulogenesis are
unclear. However, one can postulate that similar to the limb bud, these signals most likely
will consist of gradient of morphogens and differences in receptor expression (Coutinho
and Antunes 2017).
Strong evidence has been provided showing a developmental basis for many
valve diseases (Garg, Muth et al. 2005, Hinton and Yutzey 2011, Durst, Sauls et al.
2015). Therefore, it is important to recognize that mutations that occur at conception
might be asymptomatic at birth and through childhood but may result in disease
phenotypes later in life. Mitral valve prolapse for example has been described in the past
as a disease of aging, however recent studies from our lab and others have shown that
MVP is in fact a congenital heart disease with defects in valve development resulting in
impaired adult valves (Durst, Sauls et al. 2015). This idea, that developmental changes
can cause disease later in a patient’s life appears to be a reoccurring theme, as our lab and
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others have noticed (Hinton, Alfieri et al. 2008, Markwald, Norris et al. 2010, Norris,
Moreno-Rodriguez et al. 2010, Lockhart, Boukens et al. 2014, Durst, Sauls et al. 2015,
Prakash, Borreguero et al. 2017). Another well studied congenitally based cardiovascular
valve disease is bicuspid aortic valve (BAV). Patients with BAV also have
developmentally based valve disease that progresses overtime into a myxomatous
phenotype. The mechanism by which these diseases occur and progress is poorly
understood and currently the only treatment option is surgery for valve repair or
replacement. Therefore, understanding these developmental processes is essential for
determining disease mechanisms and ultimately therapeutic targets.

Bicuspid Aortic Valve Disease
Bicuspid aortic valve (BAV) disease is one of the most common congenital valvular heart
defects affecting between 0.5-1.2% of the population(Martin, Kloesel et al. 2015, Martin,
Lorca et al. 2017). BAV is just one of many left-sided heart defects such as aortic
stenosis, coarctation of the aorta, mitral valve abnormalities and hypoplastic left heart
(Martin, Kloesel et al. 2015). BAV is a congenital heart defect that results in defects in
the formation of the three aortic cusps, either by failure of one of the cusps to form or
fusion of two cusps. Often, BAV occurs with other aortic valve diseases such as
aneurism, infective endocarditis, calcific aortic valve, and thrombus formation
(Abdulkareem, Smelt et al. 2013). Patients with BAV have a higher occurrence of aortic
valve replacement and at a younger age than population norms (Joziasse, Vink et al.
2011). Clinically, BAV is usually non-syndromic but can be diagnosed in patients that
have other confounding diseases such as Marfan syndrome, Holt-Oram syndrome,
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ventricular noncompaction, adult-onset aortopathy, and Loeys-Dietz syndrome(Martin,
Kloesel et al. 2015). The etiology of non-syndromic BAV is still unclear, although
evidence suggests some form of genetic inheritance. Familial studies suggest an
autosomal dominant method for inheritance, with implications for Notch1 and GATA5 as
causal (Huntington, Hunter et al. 1997, Bonachea, Chang et al. 2014).
BAV is diagnosed primarily by transthoracic echocardiography but sometimes is
confirmed by transesophageal and 3-dimensional echocardiography. Functionally, BAV
causes aortic regurgitation, aortic stenosis, infective endocarditis and dilatation of the
thoracic ascending aorta. In addition, BAV patients often have an increased risk of aortic
dissection and a high incidence of associated thoracic aortic aneurysm (TAA) formation.
Around 50% of individuals with BAV also develop thoracic aortic aneurisms with 50%
of those patients affected with aortic dissection and often death (Nadorlik, Bowman et al.
2017).
Patients with BAV often are associated with increased prevalence of aortic
aneurysm (AA). AA is described as an increase in aortic size above the normal threshold
set for characteristics such as age, gender and body mass index. In general, the growth
rate for AA is between 0.1 and 1.0 cm/year (Elefteriades 2010). The prevalence of
ascending AA with BAV ranges from 35-80% depending on the study criteria; however,
patients with AA have a substantial increase in morality risk once the aortic diameter
reaches 6cm (Davies, Gallo et al. 2006).
Multiple factors, such as genetic predisposition, epigenetic modifiers, age,
diabetic status, and molecular regulation of MMP’s and TGFβ’s, are at play regarding the
development of BAV and aneurysm. Genes such as ACTA2, MYH11, FLNA, and
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SMAD3 have been identified as contributors for non-syndromic AA while FBN1,
TGFBR1 and TGFBR2 have been implicated in the development of syndromic AA
(Abdulkareem, Smelt et al. 2013). This information may be useful in discovering a
mechanism for BAV as no genes have been found that prove to be conclusive for BAV
with AA.
One of the most common comorbidities associated with BAV is calcific aortic
valve disease (CAVD). In fact, patient with BAV are more likely to develop CAVD with
more than 50% of patients having severe aortic stenosis and requiring valve
replacement(Peeters, Meex et al. 2017). CAVD develops when the mesenchymal cells of
the aortic valve differentiate into bone precursors and start producing excess calcific
ECM. During CAVD genes expressed during early valve development such as Sox9 are
reactivated along with regulatory proteins that promote the development of cartilage and
bone lineages(Wirrig and Yutzey 2014). CAVD occurs in two steps, first endothelial cells
are activated or damaged leading to an immune response and second, fibrosis and
increased calcification occurs. These changes then lead stiffening of the aorta and valves
resulting in improper hemodynamic forces. CAVD is caused by complex interactions
between multiple risk factors such as genetic mutations, environment, and
biomechanics(Huk, Austin et al. 2016). Currently there is no treatment other than surgery
because of the limited knowledge of underlying mechanisms.
The mechanisms underlying CAVD is still poorly understood, however, evidence
suggests that disease progression is driven by Notch, osteoprotegerin, Wnts and BMPs.
Calcification has been seen in adult mice with mutations in Notch1 or RBPJ that have
been fed a high fat diet (Garg, Muth et al. 2005, Nus, MacGrogan et al. 2011). In
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addition, mice with endothelial deletion of the Notch1 ligand Jag1 have valve
calcification later in life. It is believed that this process occurs through regulation of Hes
and Hey, downstream transcription factors in the Notch pathway that regulate
transcription of Runx2. In addition to Notch signaling, regulation of Sox9 may be
important for development of calcific valves. Heterozygous loss of Sox9 using a Col2a1
cre results in aortic valve calcification (Lincoln, Kist et al. 2007).
In nearly all cases of severe BAV aortic dilation occur resulting in altered
hemodynamic stresses and triggering increased MMP release. There are two theories for
why the aortic dilatation occurs; either from hemodynamic stresses felt because of the
bicuspid morphology or through disruption of developmental programs(Jain, Engleka et
al. 2011, Longobardo, Jain et al. 2016). Often in BAV patients a wrinkling and folding of
the cusp can occur causing an abnormality in the blood jet that is formed when compared
to normal tricuspid aortic valves (Abdulkareem, Smelt et al. 2013). However, abnormal
flow patterns cannot account for all BAV as hemodynamic forces do not correlate with
aneurysm size seen in BAV patients (Martin, Kloesel et al. 2015).
The genetic underpinnings of BAV are still unclear although familial studies have
provided evidence for a potential autosomal-dominant pattern. Family recurrence rate for
patients with BAV is approximately 35% (Huntington, Hunter et al. 1997). Family
members of patients with BAV often display BAV as well as other left-sided CHD. In
seemingly sporadic cases of BAV, epidemiological studies have identified a 10%
increased risk of BAV in siblings and offspring. For this reason, the American Heart
Association and American College of Cardiology recommends screening of first-degree
relatives of affected adults (Nadorlik, Bowman et al. 2017). Preliminary evidence shows
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that children who may be asymptomatic are at risk for increased ascending aortopathies
(Nadorlik, Bowman et al. 2017). While there appears to be a genetic link for BAV strong
genetic evidence has not been provided to account for a large majority of cases. Although
not inclusive, mutations in Notch1 and GATA5 have been identity in some patients with
BAV. In a large study, a family with aortic valve disease was screened for candidate
genes. Linkage analysis was preformed to identify a single locus on chromosome 9. From
this screen, NOTCH1 was identified and direct sequencing of NOTCH1 in affected
patients identified a mutation in the gene(Garg, Muth et al. 2005).
GATA5 has also been implicated in the development of BAV. Mice with
endocardial cushion deletion of GATA5 results in right non-coronary BAV
formation(Laforest, Andelfinger et al. 2011). GATA5 signals through both Tbx20 and
Notch to regulate cell proliferation and migration of cells within the cushions. Loss of
GATA5 results in decreased mesenchymal cells within the cushions. This however was
not a very high penetrant phenotype with only 25% of knockout mice developing BAV.
Human studies have also suggested a link between BAV and GATA5
mutations(Padang, Bagnall et al. 2012, Bonachea, Chang et al. 2014). Four rare nonsynonymous variations within the GATA5 transcriptional activation domains were found
from a large screen of 100 patients with BAV(Padang, Bagnall et al. 2012).

An

additional screen for mutations in GATA5 was done on 78 patients with BAV(Bonachea,
Chang et al. 2014). Sequencing data found two rare sequence variants in the GATA5
gene with an estimated prevalence of 2.6%. These studies provide evidence for GATA5
in the development of BAV however they are not explanatory in all cases. In addition to
Notch1 and GATA5, links have been made between BAV and a variety of genes, Tgfβ,
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KCNJ2, fibrillin, and nitric oxide synthase. More specifically, Tgfβ signaling has proved
to be disrupted in patients with BAV and AA. During valve development, Tgfβ is
important for EMT, cell migration and regulation of matrix deposition, processes that are
often affected in patients with BAV. Mutations in Tgfβ have been found in humans with
Loeys-Diets syndrome, a disease frequently diagnosed in patients with BAV(Loeys, Chen
et al. 2005, Martin, Kloesel et al. 2015).
Since BAV is a congenitally based disease, understanding the mechanisms that
occur during development are important for understanding disease pathogenesis.
Currently, little is understood about how a bicuspid instead of tricuspid valve forms. It is
possible that this occurs from fusion of two leaflets or failure of one of the leaflets to
form (De Mozzi, Longo et al. 2008). Normally the two leaflets that form are of unequal
size with the larger leaflet having a central raphe or ridge that results from fusion of the
commissures (Siu and Silversides 2010). The presence and position of the raphe varies
among patients and diagnosis of a raphe or tricuspid valve can be contested between
surgeon and pathologists (Joziasse, Vink et al. 2011). The fusion of the leaflets can occur
in three ways, right-left, right-non-coronary, and left non-coronary(Nadorlik, Bowman et
al. 2017). The most common fusion is of the right and left coronary cusps affecting about
70% of BAVs. While right/left fusion is the most common, right non-coronary fusion is
associated with BAV in patients. (Siu and Silversides 2010).
The aortic valves form from a multi-step process as described above. Briefly,
formation of the valve starts with expression of ECM from myocytes and overlying
endocardial cells forming the cardiac jelly, migration of cells into the jelly (EMT of
endothelial and neural crest cells), proliferation and finally elongation of the cusps. It is
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therefore logical that multiple mechanisms could explain improper formation of the cusps
or the etiology of BAV. Improper migration of the neural crest cells as well as disruption
in extracellular matrix deposition could be potential etiologies. More specifically, during
development, disrupted Notch signaling can lead to disruptions in neural crest cell
patterns resulting in BAV(Jain, Engleka et al. 2011).
Maintaining proper balance of ECM is important for aorta and valve biology and
disruption of proper ECM maintenance results in disease. Mature aortic valve structure
consists of three distinct layers, the fibrosa, spongiosa, and ventricularis. Each layer is
composed of specified ECM which functions to facilitate a functional valve. Matrix
metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) are secreted by
smooth muscle cells from the aortic wall, fibroblasts, and endothelial cells and regulate
this balance of ECM. Disruption of this process results in dysfunctional valve cusps.
Patients with BAV often have decreased aortic elasticity, reduced fibrillin-1 content and
increased MMP activity supporting a role for disruption of ECM boundaries in valve
disease (Joziasse, Vink et al. 2011, Abdulkareem, Smelt et al. 2013).

Mitral Valve Prolapse
In the 2017 American Heart Association report, mitral valve prolapse (MVP) was
reported as the most common valvular disease. Worldwide, MVP has been shown to
affect 1 in 40 individuals and for this reason it is a major health care burden (Freed,
Benjamin et al. 2002). Originally described in the 1960’s, MVP is described as a very
common Mendelian cardiovascular disorder characterized by the systolic displacement of
the mitral leaflets above the line of the annulus into the left atrium (Barlow and Bosman
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1966). Structurally, the leaflets are described as myxomatous, or having increased
proteoglycans, elastins, and fragmented collagens. Although often clinically benign,
MVP is often associated with mitral regurgitation, bacterial endocarditis, congestive heart
failure, atrial fibrillation and even sudden cardiac death (Freed, Acierno et al. 2003).
Currently there isn’t any non-surgical treatment for MVP most likely due to lack of
understanding of the molecular and genetic causes of the disease. This lack of
understanding combined with the increased population affected by the disease makes
finding alternative treatments imperative.
MVP can be present with other diseases (syndromic) or independently (nonsyndromic). Syndromic MVP can occur with diseases such as in Marfan syndrome while
non-syndromic MVP is an isolated valve event. Clues from familial studies have shown
non-syndromic MVP to be a genetically heterogeneous autosomal dominant trait that has
both sex and age-dependent penetrance. (Freed, Acierno et al. 2003). Increasing evidence
suggests that congenital valve malformations and disruption of developmentally
regulated pathways may lead to MVP or myxomatous valve disease later in life.
MVP is characterized by the billowing of one or both leaflets back into the atria
during ventricular systole. MVP patients have significantly elongated leaflets, increased
left atrial size and mitral regurgitation(Freed, Benjamin et al. 2002, Freed, Acierno et al.
2003). The Framingham Heart study was pivotal because for the first time MVP
diagnostics was described in detail by echocardiography(Freed, Levy et al. 1999). Until
recently, published data suggested the prevalence of MVP to be between 5 and 15% even
up to 35% in some studies (Freed, Levy et al. 1999). Many patients were misdiagnosed
because clinicians did not understand the proper anatomical dimensions of the mitral

36

annulus. In this study, investigators were able to enroll large numbers of patients with
familial MVP in order to determine the prevalence of disease in a way that used the
proper anatomical dimensions of the annulus. Through this study the rate of false positive
diagnosis has decreased with a prevalence of 1.3% of patients enrolled in the study being
diagnosed with MVP. From this study a more concrete understanding of diagnosis was
reached. Additionally, they found that complications that were often associated with
prolapse such as heart failure, atrial fibrillation, cerebrovascular disease and syncope
were not higher among subjects with MVP than among those without MVP.
In healthy mitral valves, the structure of the leaflets plays an important role in
their proper function. The valve is composed of three distinct layers composed of
collagens, proteoglycans and elastins. Both mouse and human valves appear to have these
boundaries although there is slight variation on how many ECM zones exist. Structurally,
patients with MVP have valves that have undergone myxomatous degeneration, which is
characterized by excess deposition of proteoglycans and collagens with fragmentation of
collagens and elastins. In addition to the myxomatous changes that occur in the valve, the
endothelial boundary is often perturbed (Barlow and Pocock 1985, Anyanwu and Adams
2007, Bischoff, Casanovas et al. 2016). Structural changes within the leaflet during
myxomatous degeneration prevent the leaflets from properly functioning. Over time, the
constant mechanical pressures felt by the valve lead to elongated mitral chords resulting
in a flailing leaflet. As a whole, changes in ECM, valvular interstitial cells (VIC)
activation and valvular endothelial cells (VEC) disruption contribute to the anatomical
defects that define the myxomatous valve phenotype.
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Two types of myxomatous degeneration in patients with MVP have been
described, Barlow’s disease (BD) and fibroelastic deficiency (FED). BD valves tend to be
thickened with elongated chordae, which sometimes can be thickened fused or even
calcified. Structurally, these valves exhibit myxoid infiltration, blurring of the structural
boundaries, and collagen alterations(Barlow and Pocock 1985, Anyanwu and Adams
2007, Hjortnaes, Keegan et al. 2016). BD valves are often much larger than normal
valves with anterior leaflet size at 38mm or greater(Anyanwu and Adams 2007).
Increased proliferation, and high proteolytic enzyme activity are often seen (Hjortnaes,
Keegan et al. 2016). The annulus in patients with Barlow’s disease is always dilated and
often there is sever posterior annular dilation. Calcification of the annulus is sometimes
found. In FED however the valve tissue is different. FED valves have connective tissue
deficiencies. Instead of enlarged valves as seen in BD, they often have thinned valves as
a result of deficiencies in collagen, elastins and proteoglycans with preserved leaflet
architecture (Anyanwu and Adams 2007). Chordae in these patients tend to be thicker
with increased elastin and collagen(Hjortnaes, Keegan et al. 2016). Molecularly, FED
valves have increased elastin, pERK and SMAD2 (Hjortnaes, Keegan et al. 2016). In
both diseases, activated VICs with increased a-SMA, vimentin, and MMPs are observed.

Genetic Discoveries in MVP
Determining the genetic contribution of MVP has proved to be a difficult
undertaking. Prior to the proper diagnosis criteria clinicians based diagnosis on singledimensional and eventually 2D echocardiography(Barlow and Bosman 1966). Using
these parameters, diagnosis for MVP resulted in decreased specificity. It wasn’t until the
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saddle shaped description of the valve that specificity increased without loss of
sensitivity(Freed, Levy et al. 1999). With proper diagnosis implemented and the
phenotypic basis for MVP understood, researchers have been able to make advances on
the genetic contribution to the disease. The first locus for autosomal dominant MVP,
MMVP-1 was mapped in 1999 by Disse et al. Through familial screens, they were able to
show significant linkage for markers mapping to chromosome 16p(Disse, Abergel et al.
1999). They also found that among the four large families, linkage could be confirmed on
only two. This demonstrated the genetic heterogeneity of the disease. In 2003 a study by
Freed et al discovered a second locus for MVP (MMVP2) mapping to chromosome
11p15.4 in a large family with inherited MVP(Freed, Acierno et al. 2003). The gene
involved in X-linked myxomatous valvular dystrophy (XMVD), Filamin A, was
discovered in 2007 by Kyndt et al. This was the first gene described as being responsible
for isolated nonsyndromic valvulopathy. With the founding of the first ever transatlantic
network to study mitral valve disease in 2006 the leading investigators, including
members of our group, in mitral valve disease all over the world came together to find the
causal genes involved in non-syndromic MVP. From this collaboration, our group was
able to identify the first gene for MVP, DCHS1(Durst, Sauls et al. 2015). In this study,
three large families with inherited MVP were studied. Deep sequencing and linkage
analysis revealed a region on chromosome 11 as potentially causal. Capture sequencing
of the linkage interval identified two mutations in the DCHS1 gene among the three
families(Durst, Sauls et al. 2015). In addition, loss of Dchs1 as being causal was verified
using a global heterozygous mouse model. This is the first mouse model for MVP
described and is valuable for future studies of diseases mechanisms. These major genetic

39

studies have proved invaluable in further understanding the mechanism of disease
progression and have been the starting point for this thesis work.

Primary Cilia
Current evidence from our lab and others in the literature has pointed to an
association of mutations in genes involved in primary cilia signaling and function with
cardiac diseases. Primary cilia can be thought of as the antenna of the cell. They have
been shown to function as mechano-sensors and chemo-sensors to regulate many
essential pathways(Pala, Alomari et al. 2017). Defects in either motile or non-motile cilia
have been shown to affect almost all parts of the body, therefore illustrating the
importance of proper cilia assembly and function. Primary cilia defects can be caused by
multiple mechanisms such as defect in cilia formation, signal transduction components or
trafficking.
Any defect in cilia structure or function is termed a ciliopathy. A large collection
of ciliopathies have been described including Joubert syndrome (JBTS), Meckel
syndrome (MKS), nephronophthisis (NPHP) and Bardet-Biedl syndrome (BBS) (Wang,
Li et al. 2017). Interestingly these ciliopathies also are associated with valve disease
(Karp, Grosse-Wortmann et al. 2012). Polycystic kidney disease (PKD), for example has
been associated with MVP and increased prevalence of aortic aneurysm(Smyth, Snyder et
al. 2003). Studies have reported that 25% of patients with PKD also have MVP(Lumiaho,
Ikaheimo et al. 2001). In patients with JBTS, aortic stenosis and BAV have been
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observed (Karp, Grosse-Wortmann et al. 2012). Bardet-Biedl syndrome (BBS) has been
linked with both MVP and aortic valve deficiencies(Mukta, Tiwari et al. 2008, Purkait,
Roy et al. 2012). The mechanism by which cilia dysfunction can cause valve disease and
whether the valve defects in ciliopathy patients is a primary defect of disrupted cilia is
not known. Better understanding of this link may provide valuable insight into currently
lacking diseases etiology.
The observation of the cilia is as old as the discovery of the microscope, dating
back to the times of Antoine van Leeuwenhoek in 1632 (Fuchs 1984). Cilia are
microtubule-based structures that are composed of an axoneme, basal body, and
transition zone. The axoneme acts as a molecular highway allowing proteins to traffic up
and down carrying cargo (Fig 1.2). The basal body, which is originally derived from the
centrosome of dividing cells, acts to anchor the axoneme in place. Almost all cells have
either a single non-motile, primary cilium, or multiple motile cilia. These classifications
help dictate the cilia’s role in different tissues.
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Figure 1.2 The Primary Cilia is a Signaling Hub for the Cell. Cartoon of the primary cilia showing
the axoneme with microtubule structures in green and the basal body in red. Signaling molecules are
found at the base, along the axoneme, and in the transition zone of the cilia. Proteins traffic to the cilia
through the trans-golgi network. There they are packaged in vesicles attached to Rab8. Primary cilia
are composed of a 9 + 0 outer microtubule doublets structure while motile cilia are composed of a 9 +
2 structure.
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Motile cilia, also known as flagella in some cases, can be found as the propelling
force of sperm, Paramecium, and in the lining of the trachea where they move mucus.
They can be found in the developing embryo on nodal cells helping to direct fluid flow
and determine left right laterality. Structurally, motile cilia are described as having a 9+2
microtubule doublet structure which connects to a central pair of microtubules to the
axonemal inner and outer dynein arms in order to power the cilia and allow it to move.
Primary cilia on the other hand are found one per cell and are non-motile. They act as
molecular signaling antenna which relay information to the cell. The axoneme or antenna
like structure of the primary cilia is surrounded by a lipid bilayer membrane that is
continuous with the cell membrane but is enriched with specific proteins involved in
signaling pathways. Many major signaling pathways such as Notch1, BMP, TGFB,
PDGF, Hedgehog, and PKD, have been shown to signal through the primary cilia.
Receptors from these pathways can be found on the axoneme or within the ciliary pocket
near the basal body. Loss of the primary cilia structure has been shown to disrupt these
signaling pathways and leading to changes in downstream gene expression.
The basal body of the primary cilia has been shown to be the point of localization
of multiple proteins associated with cilia formation in addition to centrosomal and
pericentriolar proteins. The ciliary membrane is contiguous with the plasma membrane of
the cell, so in order to keep signaling compartmentalized, the cilium have a transition
zone. The transitions zone acts as a gate allowing only proteins involved in cilia structure
and/or function into the primary cilia.(Garcia-Gonzalo and Reiter 2017)
Proper cilia function is dependent on proper formation of the cilia, also known as
ciliogenesis. This process is very complex and requires spatial and temporal expression
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of a vast repertoire of ciliogenic proteins in a tissue and cell-specific manner. Briefly,
ciliogenesis is composed of three steps. First, the mother centriole is modified to become
the basal body at which point it attaches to the plasma membrane through its distal
appendages. Then the transition zone is formed and finally the rest of the axoneme
extends out from the cell body. The extension of the axoneme is constructed and
maintained by the intraflagellar transport (IFT) machinery composed of kinesins, dyneins
and IFTA and B molecules(Reiter and Leroux 2017). IFT proteins are essential for
primary cilia structure and function. IFT-A and IFT-B form large platforms transporting
cargo between the base and tip of the cilium. Ift88 is a component of the IFT-B complex
along with Ift172, Ift52 and Ift57. Removal of any of these components results in loss of
primary cilia and loss of response to Hh ligands. However, genetic ablation of the IFTA
complex does not result in total loss of primary cilia, just abnormal formation. These
mutants have increased Hh signaling as opposed to the lack of Hh signaling found in
IFTB mutants. Loss of any of the IFT proteins result in embryonic lethality, polydactyly,
randomization of the left-right body axis, as well as neural tube closure and patterning
defects(Murcia, Richards et al. 2000, Haycraft, Zhang et al. 2007).
One very important pathway involved with proper formation of the primary cilia
is the exocyst complex. The exocyst is an eight-member protein complex, originally
discovered in yeast, whose function is essential for exocytosis and ciliogenesis(Lipschutz
and Mostov 2002). To assemble the primary cilia, the centrosomes of the cells have to
migrate to the apical membrane. The exocyst helps in this process by assisting in basal
body migration, membrane docking and fusion of the ciliary vesicles at the site of cilium
outgrowth. The exocyst also moves proteins to and from the primary cilia through
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trafficking cargo from the ER-GOLGI membrane. In yeast, mutants of individual exocyst
members results in failure of vesicles to dock or fuse with the plasma membrane causing
accumulation of secretory vesicles within the cell. Loss of a key component of the
exocyst, Sec10, results in loss of ciliogenesis and formation of cysts in kidney cells(Zuo,
Guo et al. 2009).

Ciliary Signaling
Many signaling pathways have been shown to be reliant on the primary cilia(Pala,
Alomari et al. 2017). Various membrane bound receptors, ion channels, transporters and
downstream proteins localize to the primary cilia. Thus, cilia function as nodal signaling
hubs that can respond to various biochemical and mechanical cues. Well studied
pathways such as Notch, TGFβ, hedgehog, and PDGF, for example, rely upon the cilia
for signal transduction. The niche environment of the primary cilia allows for a unique
signaling opportunity not found elsewhere in the cell. The ciliary membrane is physically
restricted and has different protein and lipid composition than the adjacent cell membrane
(Nachury, Seeley et al. 2010). Additionally, the primary cilia has more membrane per
area than any other area in the cell and for this reason small signaling changes can have a
large effect and cell response. Changes in localization of receptors, binding of ligands,
influx of calcium, and trafficking up and down the cilia have a large impact on the cell.
All of which would not be possible in another organelle.
As shown in Figure 1, trafficking of various proteins to and within the primary
cilium has multiple functions. By localizing proteins in a spatial and temporal pattern the
primary cilium acts to coordinate signaling through regulating protein localization, gene
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expression and protein-protein interactions. Regulation of signaling by the primary cilia
can be accomplished by movement up and down the axoneme, restriction at the base or
tip, processing by enzymes within and at the base of the primary cilia and post
translational modifications. Membrane barriers and the transition zone within the cilia
help to regulate these functions. In addition, trafficking of proteins through exosomes to
the primary cilium is important for these processes. The primary cilia can facilitate
budding of the ciliary membrane at the base in order to release exosomes into the
extracellular space. In the kidney, these membrane bound vesicles carry important
biomarkers of disease state (Chacon-Heszele, Choi et al. 2014). The exocyst complex is
important for the formation of these vesicles along the ciliary axoneme forming ciliainteracting exosomes. In these ways various signals are relayed through the cell by the
primary cilia.

Hedgehog signaling
One of the best studied cilia dependent signaling pathways is the hedgehog (Hh)
pathway. Although cilia are not required for Hh signaling in Drosophila, they are
required for mammalian Hh signaling. Members of the hedgehog signaling family have
been shown to localize to the base of the primary cilia. Receptors patched (Ptch1) and
smoothened (smo) traffic up and down the ciliary axoneme in response to any of the
hedgehog ligands; sonic (Shh), indian (Ihh) or desert (Dhh). In the presence of hedgehog
signal, patched removes repression of smo allowing it to traffic into the ciliary axoneme.
Once in the axoneme, smo can then interact with Sufu suppressing its activity and
allowing for processing of Gli family members (Gli1,2, and 3). Gli transcription factors

46

can exist in both full-length active form (GliA) and cleaved repressive form (GliR). In the
absence of Hh ligand, Gli transcription factors are proteolytically cleaved into repressor
forms.
IFT is required for production of GliA and Gli3R (May, Ashique et al. 2005).
Disruption of the IFT proteins disrupts Hh signaling as well (Haycraft, Zhang et al.
2007). In mice with deletion of the IFT proteins, the Shh signaling pathway remains
inactive. This is surprising since loss of cilia results in loss of Gli3 processing into its
repressive form. However, this suggests that loss of cilia results in insufficient Gli
processing. In addition, loss of IFT result in loss of Gli2 activation of the pathway. For
the most part, Gli1 is independent of IFT signaling, except in a positive feedback
mechanism since Gli1 expression is dependent on hedgehog pathway activation.
Each Gli transcription factor plays a role in a developmental and tissue specific
manor. Gli1 is primarily an activator of the Hh pathway. Transcription of Gli1 leads to
further activation of the pathway through activation of both Gli2 and Gli3. This feedforward loop results in increased transcription of Gli1. Gli1 has been shown to regulate
downstream transcription of extracellular matrix genes. For example, Gli1 activation
leads to increased expression of collagen 1 as shown in pancreatic cancer studies (Duan,
Ma et al. 2014). In addition, Gli1 can bind to an enhancer element on osteopontin (OPN)
regulating its expression (Pritchett, Harvey et al. 2012).
The other major activator of the Hh pathway is Gli2. Gli2 activator is formed by a
cilia and smo dependent process. Upon HH interacting with Ptch1, Ptch1 is removed
from the cilia and allows Smo to enter the cilia. In the presence of Hh, Gli2 in complex
with Gli3 and SuFu are trafficked to the tip of the cilia where they accumulate. At the tip
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of the cilia this complex dissociates allowing Gli2 to become active. In models of fibrosis
such as in the liver, Gli2 has been shown to be an important regulator of fibrotic signals.
Gli2 is an upstream regulator of Sox9 and through this regulation is responsible for
osteopontin expression in hepatic stellate cells (HSC). The HSCs become activated into
proliferative myofibroblasts in response to injury and begin migrating into the
surrounding parenchymal cells. Much like in a myxomatous valve they then begin to
secrete ECM such as collagen 1 which is damaging to the tissue structure (Pritchett,
Harvey et al. 2012).
Gli3 is critical for basal suppression of the Hh pathway. Gli3 repressor is formed
in a protein kinase A (PKA) dependent manor through proteolysis. When cleaved, Nterminus acts as transcriptional repressor. Gli3 is negatively regulated by GPR161 which,
in the absence of Hh signal, activates Gαs, thereby activating adenylyl cyclase increasing
levels of cAMP and finally activating PKA. PKA then goes on to phosphorylate sites of
Gli3, targeting it for proteolysis by βTrCP/Cul1. Gli3R then moves into the nucleus and
suppresses Hh target genes. Binding of Hh to its receptor Ptch1 facilitates the removal of
Gpr161 from the cilia thereby preventing further downstream processing of Gli3 and
allowing it to remain in its full length active state. TULP3 regulates the localization of
Gpr161 in the cilia. (Mukhopadhyay and Rohatgi 2014)
The HH pathway has many proteins which act to further enhance or repress the
pathway. For example, Gli3 regulates expression of Gli1, which regulates expression of
Ptch1. (Haycraft, Banizs et al. 2005) Loss of Polaris, also known as Ift88, results in
increased Gli3A suggesting inefficient processing. Gli3R is able to repress the Hh
pathway regardless of the presence or absence of Ift88; however, there is increased Gli3A
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in the absence of Ift88. This suggest that small amounts of Gli3R is able to repress the
pathway even in the presence of Gli3A. Experiments have shown that smo accumulates at
the base of the cilia within 1hr of treatment with Shh. However, localization of smo to the
primary cilia is not sufficient for Hh signaling. Experiments with loss of retrograde
ciliary trafficking results in Hh insufficient phenotypes (Bangs and Anderson 2017).

Receptor Tyrosine Kinases
Reviewed in (Christensen, Clement et al. 2012), receptor tyrosine kinases such as platelet
derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR),
insulin-like growth factor 1 receptor (IGF1R), and fibroblast growth factor (FGF) have
all been expressed at the axoneme of primary or motile cilia. RTKs can interact with
other signaling pathways and have been implicated in cross talk with g-protein coupled
receptors to regulate ECM production. Disruption of this process results in many human
health problems and diseases that, at least in part, mimic defects observed in patients with
known ciliopathies.
Platelet derived growth factor or PDGF is a receptor tyrosine kinase that is
upregulated upon starvation and cilia formation (Clement, Mally et al. 2013). PDGFRα
localizes to the cilia while PDGFRβ localizes along the cell membrane. PDGFRα
signaling has been implicated in different types of cancers and is associated with fibrotic
diseases (Christensen, Clement et al. 2012). In some cell types localization to the primary
cilia is necessary for receptor dimerization and downstream signaling. PDGF signaling
through the cilia can regulate cell cycle and cell migration. Stimulation of PDGFRα
leads to activation of AKT and MEK1/2-ERK1/2 resulting in localization of the Na+/H+
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exchanger, NHE1, to the leading edge of the cell which is necessary for cell
migration(Clement, Mally et al. 2013). Genetic deletion of PDGFRα and β in mice
results in loss of epicardial EMT, increased fibrosis and loss of vascular smooth muscle
cell migration during vascular formation (Smith, Baek et al. 2011, Gallini, Lindblom et
al. 2016).

Calcium/PKD/ERK
Polycystic kidney disease 1 (Pkd1) and 2 (Pkd2) have been well studied for their causal
mutations in about 90% of patients with autosomal dominant polycystic kidney disease
(Avasthi, Maser et al. 2017). Mutations in either PKD1 or PKD2 result in loss of
polycystins to the ciliary membrane. Polycystin-2 interacts with polycystin 1 to regulate
calcium signaling. Pkd1 regulates G-protein signaling pathway through binding to Gα
subunits. Pkd2 functions as a calcium channel that is activated through bending of the
primary cilia(Pala, Alomari et al. 2017). Pkd1 and Pkd2 dimerize and together function
with ryanodine receptors to mediate transduction of extracellular mechanical stimulus
into a calcium signaling response (Nauli, Alenghat et al. 2003). In addition to developing
PKD, mice with these mutations have a high penetrance of cardiac malformations (Wu,
Markowitz et al. 2000). One study looking at cardiac abnormalities in patients with
autosomal dominant polycystic kidney disease (ADPKD) found 25% of the patients with
PDK had MVP (Lumiaho, Ikaheimo et al. 2001). In addition to MVP, aortic regurgitation
and

left

ventricular

hypertrophy

have

been

documented

in

patients

with

ADPKD(Hossack, Leddy et al. 1988, Martinez-Vea, Bardaji et al. 1999). These data
suggest a potential role for cilia signaling in patients with MVP.
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Notch
Notch signaling is very important during development in patterning the embryo.
Notch receptors have been shown to signal though the primary cilia by regulating
cleavage of Notch (Ezratty, Stokes et al. 2011, Pala, Alomari et al. 2017). Notch
signaling occurs when ligands Delta or Jagged bind one of the four Notch receptors
(Notch1-4). Upon binding, Notch receptor is proteolytically cleaved via γ-secretase,
resulting in the formation of Notch intracellular domain (NICD). NICD translocates to
the nuclease and regulates target genes such as Hes and Hey(Tran, Sharma et al. 2014).
Evidence for the primary cilia in regulating Notch signaling has previously been shown
in skin and cardiac development. In skin development, Notch 3 signals through the
primary cilia to regulate epidermal differentiation (Ezratty, Stokes et al. 2011). The
primary cilia functions in processing Notch to generate NICD. Presenilin-2, the enzyme
responsible for Notch cleavage, localizes to the basal body and its activity has been
shown to be dependent on the primary cilium.
Prior to ligand binding Notch receptor undergoes endosomal sorting either for
recycling to the plasma membrane or for lysosomal degradation. Disruption of this
endosomal sorting complex results in over activation of Notch. Ciliary function is linked
to endosomal recycling and exosome formation and studies have shown disruption of
Notch recycling leads to increased activation of the pathway. In zebrafish and human cell
lines, loss of basal body proteins leads to an increase in expression of Notch targets
(Leitch, Lodh et al. 2014). It is thought that Notch trafficking to the cilia is controlled by
Bardet-Biedl syndrome (BBS) proteins. Loss of BBS proteins results in aberrant
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trafficking of the receptor through late endosomes to lysosomes and impaired recycling
of the Notch receptor (Leitch, Lodh et al. 2014).
Notch1 signaling also plays a role in cilia length regulation (Lopes, Lourenco et
al. 2010). Cilia length is a critical regulator of cilia function. Reduction of Notch
signaling in zebrafish results in shorter cilia while hyperactivation produces longer cilia.
In addition, changes in motile cilia length in the zebrafish node/ Kupffer’s vesicle (KV)
result in laterality defects.

Cilia in the heart
Many well studied ciliopathies have been shown to play a role in CHD and
cardiovascular disease. Large scale mutagenesis screens showed that cilia play a role in
left right patterning of the heart as well as cardiac looping(Li, Klena et al. 2015). In
addition to motile cilia, primary cilia have also been implicated in heart development and
have been shown to cause CHD when disrupted. Some well-studied CHDs such as
atrioventricular septal defects, left- right patterning, heterotaxy, conotruncal defects, and
left ventricular obstruction have been linked to defects in cilia function (Klena, Gibbs et
al. 2017). Defects in Hh signaling in the second heart field derived structure, the dorsal
mesenchymal protrusion (DMP) lead to atrioventricular septal defects (AVSDs)(Briggs,
Burns et al. 2016). Primary Cilia Dyskinesia (PCD) for example is a ciliopathy that
results in defects of ciliary motility. Predominantly PCD results in difficulty with
mucociliary clearance and organ laterality defects(Harrison, Shapiro et al. 2016). Links
have been made between PCD and CHD because 50% of patients with PCD have organ
laterality defects and 3.5-6% have cardiovascular malformations(Kennedy, Omran et al.
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2007). In addition, the tectonic protein 3 (Tctn3) localizes to the transition zone of the
cilia and forms a large complex with several ciliopathy-associated proteins. Disruption of
this protein results in incorrect heart looping(Wang, Li et al. 2017).
The first description of cilia in the heart was in 1969 by Rash et al. (Rash, Shay et
al. 1969). Through electron microscopy screens they were able to identify cilia in chick,
rabbit, mouse and lizard embryos in nonmitotic cardiomyocytes. Later in 2008, Slough et
al published a more thorough description of cilia in the heart (Slough, Cooney et al.
2008). They show cilia expression in the developing heart at E9.5 in both myocardium
and cardiac endothelium. They also show cilia on the endothelium of the developing
endocardial cushions although staining is not very clear. Additionally, at E12.5, they
show cilia present on the ventricular surface of trabeculations as well as in the developing
valves. Global deletion of Kif3a (a critical motor protein needed for driving ciliogenesis)
results in failure of cardiac cilia to form and disrupted formation of endocardial cushions
with decreased cellularity. These studies however lack data identifying the effects of cilia
loss into postnatal valve development, due to embryonic lethality of the global knockout.
They also suggest that the cilia function as mechanosensors since they are expressed
during the stage of heart development, which rely on sensing blood flow for
morphogenesis. They hypothesize that cilia function in different ways during different
stages of cardiac development. Although this paper was not a complete description of
cilia in the heart at all stages of development they provide the first evidence that primary
cilia are present and may be playing a role in cardiac development.
In order to determine the genetics that may be involved in congenital heart
disease, large scale ENU screens were completed by Cecilia Lo’s lab(Li, Klena et al.
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2015). Screening of 87,355 chemically mutagenized mice was done to reveal 218 CHD
mouse models. From this screen 34 cilia related genes were discovered. The mutations
were in genes that regulated ciliogenesis, ciliary trafficking, and cilia signaling. Of these
genes some were found to be mutated in mice with laterality defects suggesting motile
cilia while others were found to be mutated in mice without laterality defects suggesting
non-motile primary cilia. Comparably, genes found in this screen were found to be
similar to those found in a study of human patients with CHD(Zaidi, Choi et al. 2013).
Of the mutations recovered, 12 were found in genes that are in cilia transduced
signaling pathways suggesting that ciliary signaling in the heart is important for proper
development. Major signaling pathway genes were found also found such as genes
mediating Hh, TGFβ, and Wnt signaling. The discovery of mutation in genes regulating
vesicular trafficking is also of note since vesicular trafficking and receptor recycling play
important roles in regulation of cell signaling. Mutations were found in Dynamin 2,
Ap2b1, Ap1b1 and others which have been shown to mediate endocytic receptor
recycling(Li, Klena et al. 2015, Klena, Gibbs et al. 2017).
Strong evidence from the literature suggests primary cilia as a common link
among valve diseases. Genetic evidence from our lab and others suggests that defects in
primary cilia structure and/or function result in valve disease. This thesis work aims to
better understand the relationship between primary cilia signaling and valve disease.
Starting with a hypothesis that primary cilia are important for valve development and
using this information to inform patient-based studies, we were able to discover a novel
gene for MVP and potential mechanism for BAV. The following chapters are an
illustration of this work.
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CHAPTER 2: LOSS OF PRIMARY CILIA RESULT IN BAV IN MICE
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Introduction
BAV is one of the most common cardiac diseases affecting 0.5-2% of the population. It is
the most common congenital heart disease responsible for increased morbidity and
mortality in infants.

Currently the only treatment option is surgery to replace the

damaged tissue. Complications of BAV are severe, ranging from aortic stenosis to aortic
rupture and calcific aortic valve. Familial studies have provided evidence that BAV
might be linked with autosomal dominant inheritance however the mechanistic
underpinnings are unclear.
BAV occurs when only two of the three aortic cusps form properly during
embryonic development. Often this occurs in the presence of a raphe, or a fusion line
between what would normally be two cusps. Developmentally, the aortic cusps form
from anterior second heart field, endocardially derived and neural crest cells which
migrate into the cardiac jelly early during development. Signaling cues from the
surrounding myocardium as well as endocardial cells help to orchestrate this process.
Patients with BAV often have myxomatous aortic valves and are likely to present with
other diseases such as aortic aneurism which is caused by defects in ECM structure of the
aorta. Therefore, it is likely that defects in cell migration or extracellular matrix
production is the causal factor in the development of BAV.
To date, only a few genes have been identified in pedigrees and it is clear that no
single gene-model explains BAV inheritance, thus supporting a complex genetic network
of interacting genes. However, patients with rare syndromic diseases that stem from
alterations in the structure and function of primary cilia (“ciliopathies”) exhibit BAV and
aortic stenosis (AS) as frequent cardiovascular findings, suggesting that primary cilia
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may play a broad role in disease etiology. This contention is supported by our data,
which demonstrate that primary cilia are expressed on undifferentiated aortic valve
mesenchymal cells during embryonic development and are lost as these cells differentiate
into collagen-secreting fibroblastic-like cells. This suggested a role for primary cilia in
restraining aortic valve interstitial cell (aVIC) differentiation, which was tested by
genetically ablating cilia through Cre-mediated excision of Ift88, a critical ciliogenic
gene. Loss of Ift88 resulted in abrogation of primary cilia and increased fibrogenic ECM
production. Consequentially, stratification of zonal ECM boundaries normally present in
the aortic valve were lost and a highly penetrant BAV phenotype was evident at birth.
These data support cilia as critical for restraining ECM production during aortic valve
development and broadly implicate these structures in the etiology of BAV disease in
humans.
Results
Temporal-Spatial Analyses of Primary Cilia During Aortic Valve Development
In order to determine if cilia are expressed in the aortic valve a developmental expression
panel was done. Primary cilia expression was determined by immunohistochemical stains
for ciliary markers which were then imaged using high-resolution confocal microscopy.
From this study we showed that primary cilia are expressed throughout development on
the developing VICs. Cilia are expressed on nearly all valve cells early in development
(E11.5) at which they are short protrusions averaging around 0.5-1.0µm in length
(Fig2.1). As the valve begins to develop further (E13.5-E15.5) cilia are largely absent
form VECs but remain on almost all VICs. By late developmental and postnatal time
points the expression of the primary cilia appears to be localize to specific regions of the
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valve largely the tip and atrialis regions. At this stage, the cilia length appears to have
peaked between 2-2.5µm in length. At adult time points the majority of the primary cilia
are completely absent from the valve (Fig2.1).
The localization of the primary cilia to specific regions of the valve during
development could give insight into their role. During early development, when nearly all
cells express cilia, the ECM is composed mainly of proteoglycans. As the valve develops
it begins to stratify into different layers and express collagens. This division of matrix
matches what we see with expression of the primary cilia. As shown in Figure 2, primary
cilia localize to areas high in proteoglycans. Early in development (E11.5) when the
valve is composed mainly of proteoglycans such as versican, primary cilia re-expressed
on nearly every interstitial cell. When the valve begins to elongate and mature (E17.5 and
P0) the cilia are still present in areas highly expressing proteoglycans but are largely
devoid in areas high in collagen expression (Fig 2.2). Quantification of cilia length at
postnatal day 0 shows increased cilia length in versican rich regions when compared to
collagen rich regions. This expression pattern could be explained in two ways, either the
matrix is negatively regulating the expression of the cilia or the cilia are dictating the
expression patterns of the surrounding ECM.
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Figure 2.1: Spatial and Temporal Expression of Primary Cilia during Aortic Valve Development.
(A) IHC for the ciliary axoneme (green), basal body (red), and nuclei (blue) show expression of cilia
throughout valve development. Cilia appear shorter during early embryonic stages and longer right
before and after birth. Arrow indicate valvular endothelial cells devoid of cilia (B) Quantification
of cilia length showing increased expression of cilia during embryonic development and decreased
expression during postnatal development and adult life. Cilia length increases with development.
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Figure 2.2 Primary Cilia Co-localize with Proteoglycans During Development
(A) IHC for the ciliary axoneme (green), collagen (red, top) versican (red, bottom), and nuclei (blue)
show expression of cilia throughout development. Cilia appear to be expressed highly in areas rich
in proteoglycans and less in areas high in collagen. C= conal cushions, RC= right coronary, LC=
left coronary, NC= non-coronary, Ao= aorta. (B) High magnification images of axonemes (green)
and collagen/versican (red). Arrows depict collagen rich regions expressing shortened cilia. (C)
Quantification of cilia length in both versican and collagen rich regions shows decreased average
cilia length in collagen rich regions when compared with versican rich regions, p<0.001 Students
t-test.
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This differential expression pattern could be indicative of a potential role for cilia during
development. Previous research has shown that biomechanical forces are important for
proper valve formation. It is therefore possible that the cilia present on the VICs are
sensing the changes in interstitial fluid flow within the tissue and acting as
mechanosensors to orient the proper formation of the valve. Although the function of
primary cilia as mechanosensors on non-epithelial cells is poorly known, prior work has
shown this as a possibility(Nauli, Jin et al. 2013, Nguyen and Jacobs 2013). In addition,
cilia have also been shown to function as chemosensors, which respond to growth factors
such as Notch, Wnt, Pdgf, and Hedgehog. One study on hedgehog signaling in the valve
showed normal cushion development in sonic hedgehog and smoothened Tie2
conditional knockout mice (Goddeeris, Rho et al. 2008). This is not surprising as
previous research has shown sonic (Shh) and indian (Ihh) hedgehog are not expressed in
the developing valves (Bitgood and McMahon 1995). They do show however that desert
hedgehog (Dhh) is expressed in the developing endocardium of the cushion. Therefore,
hedgehog signaling may still be playing a role in the development of the cushions
through Dhh and non-canonical hedgehog signaling. To determine if hedgehog signaling
was playing a role we began by preforming RT-PCR on cushion mesenchyme, looking
for expression of pathway members (Fig 2.3). Both receptors for the pathway, patched
and smoothened as well as downstream transcription factors, Glis, were expressed by
mouse atrioventricular cushion cells. Notably, the ligands for the pathway Shh, Ihh and
Dhh were not expressed. This was to be expected as previous research shows no
expression of Shh and Ihh in the valves and expression of Dhh only in the VECs(Bitgood
and McMahon 1995)
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Figure 2.3. Hedgehog Signaling Components are Expressed in VICs. RT-PCR done
on mouse AVC cells. RNA was extracted from AVC cells and reverse transcription was
done to get DNA. Gels show expression of Hh receptors smoothened and patched.
Expression of the downstream Gli transcription factors are also observed. No expression
of Hh ligands Shh, Ihh, or Dhh is observed. (-) represents negative control, no DNA.
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Expression of smoothened was confirmed by 3D-immunohistochemistry (3D-IHC) on
aortic valve interstitial cells during development. Data show smoothened on the axoneme
of the primary cilia which is indicative of active Hh signaling (Fig 2.4 A). In the absence
of Hh ligand, patched represses smoothened and prevents its entry into the primary
cilium. In the presence of Hh ligand, during active signaling, patched relieves its
repression and smoothened is allowed to enter the primary cilia. In addition, IHC staining
shows nuclear expression of downstream Gli3 transcription factor at postnatal day 0 (Fig
2.4 B). These data suggest that active Hh signaling is occurring in the aortic valves
through crosstalk between endothelial secreting Dhh and VICs expressing primary cilia.
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Figure 2.4 Active Hedgehog Signaling Occurs in the Developing Aortic Valves. A.
3D-IHC showing expression of smoothened (red) on the axoneme (green) of the primary
cilia. Arrow heads show activated smoothened. B. IHC showing nuclear localization of
Gli3 (red) in P0 aortic valves. RC=right coronary, LC=left coronary, NC=non-coronary,
AO=aorta. LC=left coronary, NC=non-coronary, AO=aorta.
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To determine if cilia are functionally important a mouse model with valve specific cilia
deletion was used. One model for cilia ablation is the Ift88 conditional mouse created by
Brad Yoder’s lab (Haycraft, Zhang et al. 2007). Ift88 is an intraflagellar transport protein
that acts as a scaffold for vesicle transport up and down the ciliary axoneme. It has been
shown to be essential for the formation and maintenance of primary cilia. Loss of Ift88
results in either total deletion or very short ciliary axonemes and global deletion is early
embryonic lethal (Pazour, Dickert et al. 2000, Veland, Awan et al. 2009). Since global
deletion of primary cilia is embryonic lethal, the cardiac specific Nfatc1 cre mouse was
used to breed with the conditional Ift88 mouse. The aortic valves are composed of
anterior second heart field progenitors, endocardial and endocardial derived cells as well
as a small population of migrating neural crest cells (Leung, Liu et al. 2015, Koenig,
Lincoln et al. 2017). Therefore, the Nfatc1 cre mouse was used in order to produce a
valve specific deletion of Ift88. To confirm cilia expression was gone in the conditional
knockout animals, immunohistochemical stains for primary cilia were performed. Stains
show loss or very short axonemes in conditional knockout animals and normal cilia
structure in the wild type animals (Fig 2.5).
To confirm cilia expression was gone in the conditional knockout animals,
immunohistochemical stains for primary cilia were performed. Stains show loss or very
short axonemes in conditional knockout animals and normal cilia structure in the wild
type animals (Fig 2.5).
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Figure 2.5 Cilia Expression is Lost in Ift88f/f Nfatc1cre+ Mice. IHC showing
loss of cilia expression in conditional knockout animals. Axonemes in green and basal
bodies in red. Arrows pointing to cilia expression; arrow heads pointing to loss or
shortened cilia.
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Structural defects were observed in conditional knockout valves. Histology
showed merging of hinge regions between the right and non-coronary leaflets indicative
of a bicuspid valve (Fig 2.6). Three-dimensional reconstruction showed the formation of
two instead of three cusps in the conditional knockout when compared to litter mate
controls. This bicuspid phenotype was observed in a high percentage of all knockouts
examined, about 68 percent, with about ten percent showing a raphe like fusion. In
addition, volume measurements were taken and the right coronary leaflet of the
conditional knockout was significantly larger when compared to wild type controls.
Since increased extracellular matrix is one of the hallmarks of diseased valves, we
tested whether alterations in ECM production were evident in the fused NfatC1/Ift88
aortic cusps. Immunofluorescence staining shows increased expression of ECM protein.
At postnatal day 0 conditional knockouts have increased expression of versican, and
collagen1α1 (Fig 2.7).
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Figure 2.6 Conditional deletion of Ift88 results in BAV. H and E staining
showing fusion of right coronary (RC) and non-coronary (NC) leaflets in the conditional
knockout. LC=left coronary. 3D reconstructions show BAV phenotype in conditional
knockouts. Graphs depicts percentage of BAV in conditional knockouts.
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Figure 2.7 Ift88 Conditional Knockout Aortic Valves Have Increased ECM
Expression. (A) IHC for versican showing increased expression in the conditional
knockout. (B) IHC for collagen1a1 showing increased expression in the conditional
knockout. RC= Right coronary cusp, LC= Left coronary cusp.
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Additionally, this bicuspid phenotype did not appear to be caused by increased
proliferation since there was no significant difference in Ki67 or Ph3 positive cells in
conditional knockouts when compared to controls (Fig 2.8). When total cell number was
counted, there was also no significant difference between conditional knockout and wild
type. These data suggest that loss of primary cilia in the aortic valve does not result in
increased proliferation or migration of cells into the leaflet.
In addition to seeing increased extracellular matrix, we observed decreased cell
density in the Nfatc1cre+; Ift88f/f mice. Observations from H and E staining showed less
cells within specific regions suggesting that the enlarged aortic valve could be caused by
increased matrix (Fig 2.9). Nuclei from a specified region within the valve were counted
in order to determine nuclear density within the tissue. These data indicate that the valve
ECM is expanding and this change can explain the increased valve size seen in the
conditional knockouts.

70

Figure 2.8 Loss of Primary Cilia does not Affect Proliferation or Infiltration of
Cells. A. IHC for Ki67 and phosphohistone H3 showing proliferating cells (red) and
Mf20 marking the myocardium (green). B. Quantification of A showing no significant
difference in proliferating cells or total cell number. Students t test was used to determine
significance p>0.05. RC= right coronary, LC= left coronary.
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Figure 2.9 Conditional Ablation of Primary Cilia Results in Decreased Cell Density.
A. H and E of P0 aortic leaflets show decreased nuclei density at both the base and tip of
the right, right non-coronary leaflet (RNC). B. Quantification of A showing decreased
cell density between conditional knockout and control at the base and tip of the leaflet.
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Increased proteoglycans and fragmented collagen is indicative of diseased valves
so we next looked at the adult mice to determine if loss of primary cilia leads to adult
aortic disease. Staining’s showed similar trends to that observed during postnatal time
points. Nfatc1cre+;Ift88f/f mice had increased expression of collagen and versican with
enlarged myxomatous cusps (Fig 2.10). Quantification of cell density also showed
decreased cell density in conditional knockout cusps (Fig 2.11). Cells within a specified
area of the valve were quantified and conditional knockout valves has increased ECM
expression and decreased cell density.
Next, we wanted to look at the type of collagen produced in these valves to
determine if collagen synthesis was being affected. To do this herovici stains were done
on adult conditional knockout and wild-type control valves. Data show increased
expression of newly synthesized collagen and decreased expression of full length mature
collagen (Fig 2.11).
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Figure 2.10 Loss of Primary Cilia results in myxomatous adult BAV. IHC, left and
middle panel, show collagen and versican staining in red and mf20 myocardial staining in
green. Movat’s pentachrome stain, right panel, shows mixing of ECM boundaries with
increased proteoglycan (blue) and collagen (yellow) in the conditional knockout cusps.
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Figure 2.11 Loss of Primary Cilia Leads to Decreased Cell Density in Adult Aortic
Valves. A. IHC for versican (red) and nuclei (blue) show less nuclei in the conditional
knockout compared with control. B. Quantification of A showing significant difference
between cell density in conditional knockout valve when compared to control.
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Figure 2.12 Loss of Primary Cilia results in decreased mature collagen expression. A. Herovici’s
stains showing mature collagen in red and immature collagen in blue. Conditional knockout valves
have decreased full length collagen when compared to controls. B. Quantification of A, there is a
statistically significant decrease in full length collagen in the conditional knockout valves when
compared to controls. Students T-test, p<0.001.
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This, along with the previous data, suggest that primary cilia are needed during
development to regulate cell maturation and extracellular matrix production. The
Herovici staining showed decreased expression of full length collagen suggesting that
loss of primary cilia in valve cells during development results in a high turnover or
fragmentation of collagen.
Discussion
The genetic underpinnings of BAV are currently not well understood. These studies are
the first description of primary cilia expression in the aortic valves during development.
These data show that primary cilia are important for proper valve development and may
play a prominent role in the development of BAV. Primary cilia act to promote VIC
differentiation and therefore proper ECM production. In this way the primary cilia act to
direct valve architecture during development allowing for proper function. When primary
cilia or signaling through the primary cilia is prematurely lost, accelerated differentiation
occurs. This results in VICs that are overproducing ECM, which ultimately results in
myxomatous BAV.
Future studies are needed to determine the molecular mechanisms that underlie
this phenotype although evidence suggest that primary cilia regulate ECM production
though activation of the dessert hedgehog signaling pathway. Previous research shows
Gli transcription factors play a role in regulating ECM gene expression such as collagen
(Bolanos, Milla et al. 2012, Amano, Densmore et al. 2014, Duan, Ma et al. 2014). To
better understand the role primary cilia may be playing in valve development and disease
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we could perform RNA seq on isolated valve leaflets both wildtype and conditional
knockout mice at early embryonic times such as E13.5 and at postnatal time points such
as P0. These data could be informative as to when this change in matrix is occurring and
if the genes in the hedgehog pathway are involved. Additional experiments looking at
target genes of Gli transcription factors could give insight into what genes the Gli factors
are regulating in the aortic valves. Chip-Seq experiments with pulldown of Gli3 and
sequencing of its targets would show what genes Gli3 is regulating. In addition, looking
at non-canonical hedgehog signaling may be informative. Studies have shown hedgehog
ligands signaling through other pathways independent of Gli transcription factors (Fei,
Sanchez-Mejias et al. 2012).
In order to further investigate the hedgehog signaling pathway other conditional
knockout mice could be used. Analysis of the smoothened conditional knockout mouse
would help to determine if the hedgehog signaling pathway plays a role in this valve
phenotype. If smoothened conditional mice develop BAV then it would provide evidence
that this pathway plays a role. In addition, some in vitro studies could be performed by
treating mouse atrioventricular cushion cells with Dhh to see if Gli processing is affected.
Culturing of VICs from conditional knockout and control valves could be used also for
treatment with Dhh followed by western blots looking at Gli processing. Cyclopamine, an
inhibitor of the Hh signaling pathway could be used to treat the control valve tissue in
order to show that inhibition of the Hh signaling pathway is regulating this change in the
Ift88 conditional mice.
Additional pathways may also play a role in this process. Cilia have been shown
to regulate many important developmental pathways such as Wnt, TGFβ, PDGF and
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Notch. Since Notch gene mutations have been implemented in the development of BAV
this pathway might be good to investigate. Histological stains for cleaved notch in
knockout and wildtype mice would show if notch cleavage is affected in this model. The
PDGFR pathway may also play a role in the BAV phenotype we observed. PDGFα
localizes to the primary cilia and can play a role in ERK signaling. In addition, PDGF is
regulated by TGFβ which plays an important role in valve development and the
progression of myxomatous disease (Narine, De Wever et al. 2006, Maredia, Greenway
et al. 2017, Peng, Yan et al. 2017). There is also a strong association in pregnant mothers
of circulating lymphatic PDGF with offspring that had congenital heart disease(Steurer,
Norton et al. 2017). To test this hypothesis, leaflets from P0 Ift88 conditional knockout
and wildtype valves would be dissected and western blots would be done probing for
PDGFα and phosphorylated PDGFα as well as other members of the pathway such as
AKT, ERK and p-ERK.

79

CHAPTER 3: A DEVELOPMENTAL BASIS FOR MITRAL VALVE
PROLAPSE AS A CILIOPATHY
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Introduction
Until recently, primary cilia were thought to be vestigial evolutionary remnants
with no persisting function. Recent evidence however has shown that this is not true.
Genetic discoveries have linked mutations in cilia genes to a spectrum of rare syndromic
diseases known as ciliopathies. There is a wide range of organs affected by these
ciliopathies such as heart, kidney, skeletal or neurological tissues. One particularly
interesting finding shows a 25% comorbidity of autosomal dominant polycystic kidney
disease ADPKD and MVP. In addition, these diseases have a very similar
characterization of increased proteoglycan deposition as well as disorganization and
fragmentation of the collagen and ECM. This co-morbidity of ADPKD and MVP, as
well as their similar pathological features suggests that perhaps MVP could be a disease
of altered primary cilia function.
To begin to understand the relationship between mitral valve development and
disease we started by asking the question, “Are primary cilia expressed during
development on mitral valve tissues?”. Previous reports showing primary cilia in the
mitral valve have been vague and unclear. In order to determine if primary cilia were
expressed throughout development immunohistochemical stains for the axoneme and
basal body were done.
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Figure 3.1 Primary Cilia are Expressed During Mitral Valve Development. A. IHC
for primary cilia staining axonemes (green) basal bodies (red) and nuclei (blue) show
expression of primary cilia on VICs. Cilia expression is lost at adult stages. B.
Quantification of grouped cilia length shows ciliary length increases during development
while percent ciliated cells decreases.
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Expression patterns showed multiple interesting things. Cilia are expressed on nearly
every cell very early in development from E9.5-E11.5 (Fig 2.1A). They are expressed on
nearly all VICs and some VECs and are short in length averaging between 0.5 and 1µm
in length (Fig 3.1). As the cushion enters its differentiation and proliferation stages,
around E13.5-15.5 the cilia are expressed solely on VICs with about 85 percent of cells
expressing cilia. In addition, cilia at these stages are longer with their grouped cilia length
peaking around 1.5µm. As the valve continues to develop during later embryonic
development and postnatal time points its cilia reach peak length at around 2µm (Fig
3.1B). At adult stages, cilia expression is almost completely gone. Cilia length has been
shown to change during development in the kidney and is necessary for signaling during
development. Interestingly, ciliary expression at theses time points appear to be localized
to specific regions within the valve. Cilia length has been shown to vary by cell type
suggesting a necessity for different lengths during development(Avasthi, Maser et al.
2017). Ciliary length is regulated by the localization and quantity of IFT protein as well
as other proteins necessary for cilia assembly (Avasthi, Maser et al. 2017). Kinases have
been shown to regulate cilia length as well, acting as sensors to regulate this process. In
the kidney, cilia length increases during development (Saraga-Babic, Vukojevic et al.
2012). Data show that embryonic cilia in the collecting ducts are around 0.55µm long,
while those from postnatal cells were significantly longer at 1.23µm (Saraga-Babic,
Vukojevic et al. 2012). This change in length is also observed in the nephron, with length
changing from 0.81µm to 3.01µm (Saraga-Babic, Vukojevic et al. 2012). This is similar
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to what was observed in the mitral valve during development (Fig 3.1). This change in
cilia length provides support for cilia playing a role during embryonic development.
To show that cilia from VECs were not being broken off or missed during
sectioning, other endothelial cell types were examined. As shown in figure 3.2,
ventricular and interventricular septum endocardial cells express primary cilia. These
data suggest that primary cilia are expressed on the ventricular and septal endocardial
cells but not valvular endocardial cells during development.
To determine if the cilia expression found in mice also was found in humans, fetal
human hearts were examined. Immunohistochemical stains for primary cilia were
performed on 10 weeks and 13 weeks fetal human hearts. Staining shows primary cilia
present on the interstitial cells at both stages (Fig 3.3). Analysis of adult human mitral
valve tissues also follows a similar pattern as in mice with very few if any cilia observed
(data not shown).
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Figure 3.2. Primary Cilia are Expressed on Ventricular and Septal Endothelial
Cells. IHC showing expression of axonemes (green) and basal bodies (red) on endothelial
cells of the interventricular septum (A) and left ventricular wall (B) in developing E17.5
(A) and P0 (B) hearts. E17.5 high magnification images of the interventricular septum
(A’) and (B’) and P0 high magnification images of the left ventricular wall (A’’) and
(B’’). Arrows point to primary cilia expression.
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Figure 3.3. Primary cilia are Expressed on Fetal Human Valves. IHC (left and middle
panel) shows expression of acetylated tubulin (green) and gamma tubulin (red) on 10
week and 13-week fetal valve tissue. 3D reconstructions of IHC (right panel) shows
ciliary axonemes (green) on VICs. AL= anterior leaflet, PL= posterior leaflet.
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To better understand if primary cilia correlate with regions of ECM stratification,
IHC was preformed using antibodies against proteins that demarcate specific ECM
boundaries within the mitral valve. ECM expression during development stratifies into
specific regions of the valve that appeared to be localized with the primary cilia. To
determine if ECM and cilia were co-localizing to specific regions within the valve we
stained for two well documented ECM proteins, versican and collagen1a1.
Early during development, the AV cushions are composed mainly of
proteoglycans with little collagen expression. At this stage as shown in figure 3.1, the
cilia are short but expressed on nearly every cell. As the valve ECM begins to mature the
cilia appear to localize to specific regions in the valve mainly expressing versican. At
postnatal day 0 cilia are highly expressed in proteoglycan (versican) rich regions and are
notably absent in collagen expressing regions (Fig 3.4C). When quantified, the
percentage of ciliated cells in versican rich regions were significantly higher than the
percentage of ciliated cells in the collagen rich regions (Fig 3.4C). In addition, cilia that
are expressed in versican regions are significantly longer than those expressed in collagen
regions (Fig 3.4D). These data suggest that cilia size and number promote organization of
the valve extracellular matrix into zonal boundaries characteristic of normal mitral valve
histoarchitecture.
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Figure 3.4. Primary Cilia are Expressed in Areas Rich in Versican. (A) IHC of
posterior leaflets show primary cilia marked with acetylated tubulin (green) co-stained
with collagen (red) show few cilia within this region. (B) Immunohistochemical stains of
primary cilia marked with acetylated tubulin (green) co-stained with versican (red) show
increased expression of acetylated tubulin in areas of high versican expression. (C, D)
Quantification of IHC stains at P0 showing a 70% decrease in cilia length and a 250%
reduction in the number in collagen-rich regions. AVC=atrioventricular cushion. Dotted
line demarcates high collagen vs. low-collagen boundary.
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To determine if primary cilia are necessary for mitral valve development we took a
mouse genetics approach. As previously mentioned, Ift88 is an intraflagellar transport
protein necessary for primary cilia formation. Conditional removal of Ift88 in the valves
using the NfatC1cre driver was used to assess the role of primary cilia in the mitral valve.
To confirm that cilia were lost using this system, IHC was performed on conditional
wildtype, heterozygous and knockout animals. Staining showed partial loss of primary
cilia in heterozygous animals and complete loss or very shortened cilia in knockout
animals (Fig 3.5A). Histologically, the conditional knockout and heterozygous mice have
enlarged anterior leaflets (Fig 3.5B). 3D reconstruction of H and E staining showed a
trend towards significance of conditional heterozygous and a significant increase in
anterior leaflet volume of the conditional knockout when compared to wildtype littermate
controls (Fig 3.4C).
Primary cilia play a role in sensing fluid movements in surrounding tissues.
Motile cilia are used to propel molecules and objects across the surface of some tissues.
In addition, many studies have shown that during valve development the biomechanical
forces that are present play a major role in how the valves are formed. Therefore, one
would hypothesize that primary cilia would be expressed on the surface of the valves.
However, this is not what we observe. Very early during valve development (E9.5) we
see some VEC primordia expressing primary cilia however the percentage is very small.
Therefore, we hypothesized that the primary cilia expressed on the VICs are what is
regulating valve development. To further address this question, we conditionally deleted
Ift88 in multiple cre models during development.
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Figure 3.5 Loss of Ift88 Impairs Ciliogenesis During Development and Leads to
Enlarged Postnatal Mitral Valve. (A) IHC at postnatal day 0 show gene dosage effect
for Ift88 on axoneme (green) formation in the mitral valves (white arrow heads). (B) H
and E staining’s show that cHET and cKO have enlarged mitral leaflets. Student t-test of
valve volumes obtained from 3D-reconstructions (C) show a trend towards significance
in the cHET and a significant increase in valve volume in the cKO. AL=Anterior leaflet,
PL= Posterior Leaflet.
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Table 3.1 A list of Cre-lines and expected outcomes. VIC=valve interstitial cells,
VEC= valve endothelial cells.
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As shown in Table 3.1, conditional deletion of Ift88 using the Nfatc1en-Cre would ablate
cilia expression in only endocardial cells. We hypothesized that conditional loss of Ift88,
with cre models that are expressed in VICs (periostin and NfatC1), will result in an
enlarged valve phenotype. In addition, if ciliated VICs are regulating valve development
then conditional loss of Ift88 in VECs, using the enhancer cre, will not have a phenotype.
Data show that conditional loss of primary cilia in VICs using the periostin cre
driver results in an enlarged valve phenotype (Fig 3.6). This change trends towards
significant but is not statistically significant(anterior leaflet p=0.31, posterior leaflet
p=0.27). The anterior leaflet of these mice appear to be enlarged in specific regions and
not uniformly large (Fig 3.6). Further analysis looking at length and width measurements
might be helpful in fully characterizing this phenotype.
Surprisingly conditional loss of Ift88 with the enhancer cre driver resulted in
significantly larger posterior leaflet and an anterior leaflet that was enlarged although not
significantly so, when compared to wild type littermates (anterior leaflet p=0.03;
posterior leaflet p=0.16) (Fig 3.6). There are two possibilities for why this phenotype
may be occurring. First since we see very little to no primary cilia expression in the
endocardial cells of the valve, loss of Ift88 may be playing a cilia independent roll in
valve development. It has been shown that Ift88 can play a role in microtubule dynamics
and cell migration independent of primary cilia (Borovina and Ciruna 2013, Boehlke,
Janusch et al. 2015). There are, however, some endocardial cilia on the valves very early
during development (E9.5-10.5). The other possible explanation is that loss of primary
cilia on the endocardial cells during early valve development is enough to result in
enlarged mitral valves.
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Figure 3.6 Deletion of Ift88 using Periostin and Enhancer Cre models results in
enlarged mitral valves. A. H and E and 3D reconstruction of Ift88 periostin and
enhancer cre conditional knockout mice showed enlarged anterior leaflets when
compared to control. B. Quantification shows a trend towards a significant increase in
valve volume is seen in periostin cre posterior and anterior leaflets while a significant
increase in volume is seen in the enhancer cre posterior leaflet.
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Since there was so much variation in the phenotypes that were observed we
wanted to look at cre expression in these animals. To do this we used the Rosa26 green
fluorescence protein (GFP) reporter mouse crossed with the NfatC1, periostin, and
NfatC1-enhancer cre mice. This allows GFP expression in all cells that cre recombinase
is active.
Data show that the periostin and enhancer cre models are not as robust as originally
thought (Fig 3.7). GFP expression shows limited periostin cre activity in VICs as shown
in figure 3.7. and the enhancer cre mouse also showed limited expression. NfatC1
enhancer cre expression was seen on the ventricularius aspect of the valve with limited
expression on the atrialus. Taken together, these data suggest that partial loss of primary
cilia within the valve is sufficient to result in a phenotype. Therefore, to remain consistent
the NfatC1 cre was used for the following experiments.
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Figure 3.7. Cre Recombinase Expression Patterns. IHC for GFP shows Cre activity
under specific drivers. GFP expression in NfatC1 mice is nearly all valve cells. NfatC1
enhancer expression is localized mainly to the ventricularus aspect and is absent in the
majority of artrial endothelial cells. Periostin cre expression is found in VICs within the
anterior and posterior leaflet but is not expressed by all VICs. AL= anterior leaflet,
PL=posterior leaflet.
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One of the common themes among models with MVP is increased proliferation and since
primary cilia regulate cell cycle we began by looking for changes in proliferation. We
looked at proliferation of the Ift88 Nfatc1cre mice as a way of explaining the increase in
valve volume. Data show no significant difference in proliferating cells in conditional
heterozygous or knockout animals when compared to wild type littermates (Fig 3.8). To
determine if the increase in valve size could be explained by increase infiltration or
migration of cells, total cell numbers in each leaflet were also counted (Fig 3.8C). No
difference was observed in total cell number of wildtype or conditional heterozygous and
knockout animals. These data suggest that the increase in valve volume cannot be
explained by increased proliferation or migration of cells in the conditional knockout and
heterozygous leaflets.
Another hallmark of myxomatous valve diseases is increased ECM so the increase in
valve volume that was observed could be explained by increase in ECM. To determine if
there is more ECM in Ift88 conditional mice cell density was examined. Decreases in cell
density, but no change in total cell number, would be explained by changes in ECM
production. Decreased VIC density was observed in the anterior leaflet of conditional
knockout animals (Fig 3.9). These data were then confirmed by whole transcriptome
analyses (RNAseq) analysis.
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Figure 3.8 Loss of Primary Cilia have no Effect on Proliferation. (A) IHC for
proliferating cells stained with ki67 (red) and myocardium stained with mf20 (green). (B)
Quantification of the stains from A showing no significant difference in wildtype,
conditional heterozygous and knockout leaflets. (C) Quantification of total cells in both
anterior and posterior leaflets showed no significant difference in wildtype, conditional
heterozygous and knockout leaflets. AL= Anterior Leaflet, PL= Posterior Leaflet
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Figure 3.9 Loss of Primary Cilia Results in Decreased Cell Density. (A) H and E
showing areas of decreased cell density in the conditional knockout anterior leaflet.
Boxes show representative area where cell counts were performed at the base, middle and
tip of the leaflet. (B) Quantification of areas represented in A, at the base, middle and tip
of the anterior leaflet. There is a significant decrease in the number of cells per area at the
base, middle and tip of the anterior leaflet of the conditional knockout. Students t-test pvalue <0.001.
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Figure 3.10:

Loss of Primary Cilia Results in Increased Expression of ECM

Pathways. A. Perturbation vs. over-representation plot. The most significant change
observed in RNAseq datasets was ECM/Receptor interactions (arrow and yellow circle)
with a p-value= 1.12X10-8 B. mRNA transcript quantities of differentially expressed
ECM genes. Graphical representation of ECM genes that are significantly upregulated in
the Ift88 conditional knockout mitral valves. Genes were selected based on p<.05. C.
Pathway analyses of Differentially Expressed Genes. Pathway representation showing
genes are increased in the Ift88 conditional knockout (red) or decreased (blue) and their
intersection with receptor-mediated pathways.
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Individual leaflets from wildtype and knockout animals were dissected and extracted
RNA was analyzed. Of note markers of extracellular matrix were significantly increased
in the conditional knockouts. These data confirmed that loss of primary cilia result in
robust activation of fibrogenic and proteoglycan ECM gene programs that is consistent
with early stages of myxomatous degeneration.
Further analysis was preformed to determine if the endothelial cell number was
changed in these mice. Increases in valve volume should be associated with increases in
endothelial cell number to compensate for the increased valve sizes. However, when we
counted total endothelial cells we found that there was no change in cell number between
conditional knockouts and wild-type litter mates (Fig 3.11). This might be explained by
changes in proliferation among the endothelial cells. To address this question, stains were
done looking at proliferating endothelial cells. Again, no difference was observed
between conditional knockout and wildtype valves in both anterior and posterior leaflets
(Fig 3.11). These data suggest that loss of primary cilia results in increased valve volume
which cause endothelial cell stretching.
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Figure 3.11. Loss of Primary Cilia Results in Endothelial Cell Stretching. A. IHC
showing stains for pcam (green) marking the endothelial cells, ki67 (red) marking the
proliferating cells, and dapi (blue) staining the nuclei. B. Quantification shows no
significant difference in total endothelial cell number or proliferation of endothelial cells
in both anterior and posterior leaflets. AL= anterior leaflet, PL= posterior leaflet
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Figure 3.12. Loss of Primary Cilia Leads to Myxomatous Mitral Valve Disease. IHC
(top and middle) and Movat's staining (bottom) of 4-6 month old Ift88 deficient mice
show loss of normal versican and collagen boundaries and a myxomatous phenotype in
conditional heterozygous and knockout animals (black arrows). Movats staining shows
increased proteoglycans (blue), and collagens (yellow). AL, PL = Anterior and Posterior
Leaflets, respectively.
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To determine if these developmental changes result in adult myxomatous mitral valve
degeneration adult Ift88 conditional mice were analyzed. Histologically these mice
develop myxomatous degeneration as shown by proteoglycan and collagen accumulation
(Fig 3.12). H and E and Movat’s pentachrome stains show loss of normally stratified
valves composed of distinct zones of elastin, collagen and proteoglycan in conditional
heterozygous and knockout animals (Fig 3.12). Patients with myxomatous valve disease
and MVP have disrupted matrix boundaries and increased production of collagens as seen
in figure 3.13. The Ift88 conditional mice phenocopy the patients, having significantly
increased collagen production and disruption of matrix boundaries as marked by
increased blue staining in Herovici’s stain (Fig 3.13). Thus, loss of primary cilia causes
developmental defects that are characterized by expansion of extracellular matrix and
disrupted histological architecture that progress to an adult myxomatous valve pathology,
similar to that observed in patients with MVP.
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Figure 3.13 Ift88 Conditional Mouse Models Phenocopy Matrix Disruption and
Increased Collagen Deposition Found in Human Patient Valves. Herovici’s stains
showing immature or newly synthesized collagen in blue and mature collagen in red.
Both diseased human and mouse valves have blurring of mature and immature collagen
as well as increased production of new collagen.
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Genetic association of Primary Cilia and MVP
Based on these findings as well as evidence from the literature showing a 25%
comorbidity of ADPKD and MVP, we hypothesized that primary cilia may play a broad
role in mitral valve disease in humans. To test this hypothesis, we wanted to evaluate the
link between the current MVP genes (DCHS1 and FLNA) and ciliogenesis. IHC staining
for cilia in these mice showed significant decrease in cilia length. Dchs1 heterozygous
mice had significant decrease in the number of ciliated cells at E17.5 (Fig 3.14). 3D
reconstruction of primary cilia in these valves show significant loss of axonemes.
Quantification showed a significant decrease in the number of ciliated cells (Fig 3.14). In
addition, the Filamin A mouse model of MVP also had significant cilia loss. At postnatal
day 0 of both Dchs1 knockout and filamin A conditional knockout showed significant
decrease in average cilia length when compared to controls (Fig 3.15). These data suggest
that primacy cilia may play a role in the development of MVP regardless of the gene
involved.
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Figure 3.14 Dchs1 Heterozygous Mice have a Primary Cilia Defect. 3D reconstruction
of cilia from E17.5 posterior leaflets show loss of axonemes (green) in Dchs1+/- mice.
Red=Basal Bodies. Magnification of boxed area shown. >50% loss of cilia in VICs and
VECs (aVECs, vVecs= atrialis and ventricularis valve endothelial cells. *p<0.01.
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Figure 3.15 Decreased cilia expression in knockouts associated with MVP. (A) IHC
of P0 Dchs1 knockout and filamin-A conditional knockout mitral leaflets showing
axonemes (acetylated tubulin-green) basal bodies (gamma tubulin-red). (B, C) Grouped
cilia length of Dchs1 knockout and filamin-A conditional knockout mice show a shift in
grouped cilia length with the majority of cilia ~1.4µm in length while control P0 mice
have the majority of cilia ~2.25 µm in length, which represents a 40% decrease in cilia
length in the knockout mice with p<.001.
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We further evaluated broad involvement of the cilia pathway in MVP by
analyzing GWAS data from 1,412 MVP cases and 2,439 control samples to test for
global enrichment with significant association among a list of 278 different genes known
to be involved in primary cilia biology, mainly as harboring rare mutations in a diverse
panel of ciliopathies.
We performed SNP test ratio method on several GWAS where phenotypes of
cases and controls were permuted to generate 1000 simulated GWAS. Then, according to
a pre-defined p-value threshold, the method consisted of counting the number of times
the pathway tested included a higher ratio of significant to non-significant SNPs,
compared to the 1000 simulated GWAS (Table 3.1). As recommended for this method,
we used the KEGG pathways catalog in addition to our customized list of cilia genes.
Given the limited number of highly associated SNPs in the current GWAS, we set
significance at P<0.05 to allow more SNPs to contribute the analyses. Among nominally
associated SNPs in the GWAS, we found that SNPs that map in the cilia genes list are
more likely (P=0.03) to be enriched for associated SNPs with MVP.
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Table 3.1: GWAS Phenotypes of Cases and Controls were Permuted to Generate 1000
Simulated GWAS. Among nominally associated SNPs in the GWAS (SNPs<0.05), we found
that SNPs that map in the cilia genes list are more likely (trend P=0.034) to be enriched for
associated SNPs with MVP. Of note, this analysis highlighted at the top 10 enriched pathways
consistent cardiac enriched

pathways including

hypertrophic cardiomyopathy, dilated

cardiomyopathy and cardiac muscle contraction
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Discussion
These data show for the first time that primary cilia are necessary for proper mitral valve
development. Thorough these studies, we have shown that primary cilia are expressed
both spatially and temporally on valvular interstitial cells but not endothelial cells as
previously described. Similar to studies from the kidney, primary cilia in the heart
increase in length with development, a phenomenon which is likely important in
regulation of developmental processes occurring at the different stages. These primary
cilia localize to areas of increased proteoglycan accumulation which has strong
implications for a chemosensory roll. Further studies are needed to determine if primary
cilia regulate ECM expression or if localization of cells within a specific ECM regulates
the expression and length of a primary cilia.
Primary cilia are necessary for proper valve development and when disrupted
result in myxomatous valve disease. Our studies using the Ift88 conditional mouse model
show loss of primary cilia prematurely results in increased postnatal valve volume. This
increase in valve volume is not caused by increased proliferation, decreased apoptosis,
increased infiltration of extra-cardiac cells or increased EMT. The increase in valve
volume is caused by increased ECM expression as shown by decreased cell density and
increased ECM expression. Since fibroblasts in the valve organize matrix, this increase in
matrix could also be a loss of compaction issue. To determine this, further studies would
be needed. Matrix compaction assays could be done by embedding VICs from Ift88
control and conditional knockout mice in collagen gels and determining if the compaction
of collagen is affected more in either genotype.
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These changes shown during valve development change the structure and
stratification of ECM expression which results in myxomatous adult valves. Conditional
deletion of Ift88, and thereby primary cilia, result in myxomatous adult mitral valves. In
this model we see blurring of matrix boundaries and increased collagen and versican.
Additionally, conditional knockouts have increased collagen production indicating that
matrix turnover is affected. More work could be done to determine if these mice do
develop MVP. Echocardiography of aged mice to look for prolapse could be done.
Additionally, Dhh has been shown in the literature to be important for endothelial
boundary function and endothelial integrity. (Chapouly, Yao et al. 2016) Interestingly, in
our Ift88 conditional knockout animals we saw no difference in total endothelial cell
number. An increase in valve size but no increase in endothelial cell number suggest that
the endothelial cells within the valve would have to stretch to compensate. This stretching
may be leading to cytokine release which signals to circulating macrophages that the
tissue was damaged. In other disease models and in human patients with myxomatous
mitral valve disease, infiltration of immune cells is common.
Human data further supports the hypothesis that primary cilia are important for
proper valve function. GWAS analyses were performed on patients with MVP. Data
show, increased association of ciliary genes with MVP patients. These studies suggest
that primary cilia may play a broad role in the development of MVP. Previously
identified MVP genes, Dchs1 and FlmnA, show decreases in primary cilia length as well.
This novel finding provides further support for the role of primary cilia in valve disease.
These studies show MVP is a congenitally based disease of the primary cilia that
results in changes in ECM remodeling resulting in weakened valve leaflets. These leaflets
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over time become myxomatous. The increase in valve size leads to strain on endothelial
boundary formation ultimately leading to releases of cytokines and infiltration of
macrophages as seen in Filamin A adult mice and human patients. This process occurs
over many years in the patient’s life and therefore MVP patients are often asymptomatic
early on in life.
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CHAPTER 4: MUTATIONS IN DZIP1 CAUSE
MITRAL VALVE PROLAPSE
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Introduction
Currently little is known about the etiology of MVP. Familial studies have provided
evidence for a genetic association but until recently a causal gene has not been identified.
Informative studies from our lab has shown an association between primary cilia and
valve disease. Published literature shows a 25% comorbidity between MVP and an
established ciliopathy ADPKD. In addition, our data from Ift88 cilia knockout mice show
that primary cilia are important for valve development and cause myxomatous valve
disease when disrupted. These data suggest that primary cilia are important for proper
valve development and when disrupted play a role in the development of MVP.
In order to further evaluate the role of primary cilia in MVP, we examined our
patient data to determine if cilia genes were associated with the linked region. Analysis
was done on a multi-generational family with inherited autosomal dominion MVP
previously linked to chromosome 13 (Fig 4.1). Out of 43 individuals enrolled in the
original study, nine patients met the full clinical diagnostic criteria for MVP, with two
individuals having moderate to severe MR and one with ruptured chordae that required
surgical intervention. Additionally, six were coded as minimal MVP, and two had
prodromal pre-clinical forms, which have recently been reported to progress and have a
familial association. None of the individuals in the pedigree exhibited extracardiac
manifestations, and all MVP-affected individuals were deemed as “non-syndromic”.
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Figure 4.1 Identification of DZIP1 as an MVP gene. (A) Multigenerational family with
inherited, autosomal-dominant, non-syndromic MVP. ?= unknown phenotype.

(B)

Human transcript and marker maps of the linkage interval on chromosome 13. Candidate
region is within 13q31.3-32.1, and all RefSeq genes and their orientations are shown
within the 8.2-Mb interval. DZIP1, the only cilia gene within the locus is highlighted in
pink. (C) Western analyses and statistical analyses (t-test) for DZIP1 showing that each
of the 3-affecteds analyzed had a significant reduction (p=.016, p=.011) in DZIP1
protein expression. Sanger sequencing identified a single missense mutation within exon
5 of DZIP1 resulting in a serine to arginine change. +/- denotes DZIP1 variant in affected
individuals.
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Figure 4.2 Echocardiography of Proband from Chromosome 13 family.

(A)

Parasternal long-axis view of proband from US family showing prolapse (blue arrows)
above the annulus during ventricular systole (dotted line). (B) Significant MR is observed
in this patient (yellow arrow). (C) Thickened, myxomatous appearing mitral leaflets
(arrowheads).
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The proband of this family displayed significant bileaflet prolapse coincident with mitral
regurgitation (Fig 4.2). The linkage peak spanned 8.2 Mb and included 14 genes (Fig
4.1). In order to define the putative MVP gene(s) in this family, we used a candidatebased approach. DZIP1 was the only gene within the linkage region that had previously
been shown in other model systems to regulate ciliogenesis and/or cilia signaling.
What is Dzip1?
DZIP or DAZ-interacting protein was originally identified in zebrafish where it
was shown to interact with DAZ (Moore, Jaruzelska et al. 2004). DAZ and DAZ-like
proteins (DAZL) are expressed in the developing testies and ovary where they function in
early germ cell development. Their expression is gone by early somatic cell generation
but DZIP expression is maintained and expressed by neuronal cells. Dzip1 is a
centrosomal protein that is important for ciliogenesis, vesicle transport to the primary
cilium, and downstream Hh signaling. Loss of Dzip1 results in loss of primary cilia. In
zebrafish, the gene igu encodes for Dzip1 which is shown to localizes to lysosomes and
endosomes(Sekimizu, Nishioka et al. 2004). For this reason, Dzip1 has been implicated
shuttling proteins between the nucleus and cytoplasm.
Dzip1 is an important regulator of Hh signaling. In igu mutants, Hh signaling is
impaired with decreased Gli activator formation and increased Gli repressor suggesting
that Igu/Dzip1 function is required for full activation of Gli proteins in response to Hh
signals(Sekimizu, Nishioka et al. 2004). In addition, Dzip1 is the bridge between IFT88
and Gli3. It has been shown to bind Gli3, but not Gli1 or Gli2, preventing Gli3 protein
from entering the nucleus. Loss of Dzip1 in mice leads to accumulation of Gli3 in the
nucleus(Wang, Low et al. 2013).
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Vesicle transport also plays a very important role in the formation of the primary
cilia. In mouse embryonic fibroblasts (MEFs), Dzip1 localizes to the basal body and
shuttles IFT88 to the distal appendages of the mother centrioles during cilia
formation(Wang, Low et al. 2013). Loss of Dzip1 results in loss of primary cilia. Dzip1
localizes to the centrosome during cell division and promotes the release of Rab8GDP.
Rab8 is the core mediator of vesicle trafficking to the cilium and loss of Rab8
localization or inhibition of the formation of Rab8GDP leads to improper cilia
formation(Zhang, Zhang et al. 2015). In addition, the BBSome proteins are essential for
regulating vesicle transport and localization of proteins to the primary cilia for assembly.
First discovered in patients with Bardet-Biedl syndrome, the BBSome consists of
multiple proteins which assemble to bind and target membrane vesicles by reading
signals on vesicles destined for the ciliary membrane(Jin, White et al. 2010). Dzip1 plays
a role in this process through its binding of PCM1 which mediates the recruitment of the
BBSome to the centrosome(Zhang, Wang et al. 2017).
Results
We began our experiments by examining if Dzip1 is expressed in the developing
mitral valve. RNA in situ and IHC experiments revealed robust expression of Dzip1 in
the developing anterior and posterior mitral leaflets, with protein expression being
localized to basal bodies within mitral valve interstitial cells (Fig 4.3).
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Figure 4.3 Expression of Murine Dzip1. (A) Section in situ of Dzip1 at E14.5 showing
robust mRNA in the anterior and posterior mitral leaflets (AL, PL, respectively). (B) IHC
for Dzip1 (red) and axonemes (green) or basal bodies (green) showing expression of
Dzip1 at the basal body in E10.5 AV cushion mesenchyme.
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Western analyses of lymphoblasts from affected and unaffected family members
revealed significant down-regulation of DZIP1 protein expression (Fig 4.1). Sanger
sequencing of DZIP1 revealed a proline-to-serine change in two known DZIP1 isoforms
(p.S70R, p.S24R). Whole exome sequencing (WES) confirmed that no other coding
changes were present within the linkage interval. Sanger sequencing of all members of
the family confirmed segregation of the DZIP1 variant. A second, three-generation,
family of European descent was identified with autosomal dominant MVP, and WES
followed by Sanger sequencing identified the same P.S70R, p.S24R change in DZIP1
affected individuals (Fig 4.4). Minor allele frequency analyses in ExAC/gnomAD
revealed that this variant is exceedingly rare, and was never observed in 122,000 exomes,
and only once in 15,500 genomes. To test whether Dzip1 plays a significant role in
ciliogenesis and MVP, conditional ablation of Dzip1 (with NfatC1cre) was performed in
the mitral leaflets.
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Figure 4.4 Identification of additional MVP family with a DZIP1 mutation. (A)
Pedigree of family showing inherited, autosomal dominant MVP. += DZIP1 mutation
carrier with the same mutation (p.S24R, p.S70R) as the original family. Grey box is an
individual that lacks a DZIP1 mutation but has MVP. This individual has a different
disease presentation with more symmetrical prolapse and altered anterior displacement of
the coaptation point, suggesting a discordant phenotype unrelated to DZIP1 variants. (B,
C) Sanger sequencing showing DZIP1 mutation and reference sequences for each of the
family members.

121

Figure 4.5 Conditional deletion of Dzip1 results in increased postnatal valve
size. (A) IHC, H & E, and 3D reconstructions show loss of primary cilia (acetylated
tubulin-green) and increased valve size in conditional heterozygous and knockout mice at
P0. Basal bodies (gamma tubulin-red) and nuclei (Hoechst-blue). (B) Quantification of
3D reconstructions in A (*=p<.005). (C) Quantification of grouped cilia length in WT,
conditional heterozygous (cHET) and conditional knockout (cKO) anterior leaflets
showing decreased cilia length in cHET and cKO.
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IHC showed loss of primary cilia in conditional knockout animals and partial loss
in conditional heterozygous animals (Fig 4.5). The cilia that were present in these leaflets
were significantly shorter than their wild type littermate controls. Histologically,
conditional heterozygous and knockout animals had enlarged valve size as shown from H
and E staining as well as 3D reconstruction (Fig 4.5). Both anterior and posterior leaflet
volume of both heterozygous and knockout animals were significantly larger when
compared to wild type littermates.
Previous research has shown Dzip1 to sequester Gli3 in the cytoplasm promoting
its cleavage and preventing its localization in the nucleus (Wang, Low et al. 2013).
Therefore, we wanted to asses Gli3 processing in the Dzip1 conditional mice. Protein was
taken from single anterior leaflets of Dzip1 conditional heterozygous, knockout and
control animals. Western blots were run and probed with Gli3 antibody. Data show no
change in Gli3 cleavage between conditional heterozygous, knockout and control animals
(Fig 4.6).
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Figure 4.6 Conditional Loss of Dzip1 Does Not Change Gli3 Processing. Western blot
of mouse AV cushion cell lysate probed for Gli3 shows no change in levels of Gli3R/Fl.
B. Quantification of Gli3 western blot showing no significant difference in levels of
repressor (Gli3R) and full-length activator (Gli3FL).
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To determine if loss of Dzip1 and primary cilia play a role in the development of
mitral valve prolapse, adult mice were assessed. Additional analyses of adult Dzip1
conditional knockout mice (using either NfatC1Cre or Tie2Cre) revealed a myxomatous
phenotype with increased proteoglycans and collagen and loss of the normal ECM zonal
boundaries, observed in control mitral leaflets (Fig 4.7).
Functional echocardiographic assessment revealed that these structurally altered
mitral valves exhibited prolapse and leaflet elongation in conditional heterozygotes (2 out
of 4) and knockout animals (4 out of 5) (Fig 4.7). MVP was never observed in control
animals and there were no statistically significant alterations in ventricular contractile
function between the conditional Dzip1 heterozygote, knockout and control animals (Fig
4.8). Interestingly, we noted a gene dosage affect in which loss of one allele of Dzip1
was sufficient to perturb ciliogenesis during development and engender a mitral valve
phenotype in the adult. These data support our finding of a rare, damaging DZIP1
missense mutation in two families with MVP, which support the proposed hypothesis that
MVP is also a form of a ciliopathy.
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Figure 4.7 Loss of Dzip1 Results in Myxomatous Adult Mitral Valves. IHC
and Movat’s stains in adult Dzip1 conditional wildtype heterozygous and knockout
animals show significant enlargement in valve size and blurring of matrix boundaries.
Dzip1 conditional heterozygous and knockout animals have increased collagen (top) and
versican expression (middle) when compared to wildtype littermates.
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Figure 4.8 Dzip1 Deletion Results in MVP. Parasternal long-axis views of Dzip1
deficient mitral leaflets shows leaflet elongation and bileaflet prolapse during ventricular
systole. AL, PL= anterior and posterior leaflet respectively. Ao=Aorta
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Discussion
These data are the first to show cilia are important for the proper development of the
mitral valve. Disruption of cilia through deletion of Dzip1 results in enlarged postnatal
mitral leaflet that develop into myxomatous adult valves. Loss of Dzip1 results in MVP
in adult mice as shown by echocardiography and this phenotype is what is seen in
patients with Dzip1 mutations. Further studies need to be done to identify a mechanism
by which Dzip1 mutations result in decreased cilia length. Preliminary data in the lab
suggest that this mutation may disrupt binding to important molecules involved in
ciliogenesis. Generation of the point mutation mouse has provided insight into the
biology of the patients with Dzip1 mutations. Preliminary data from these Dzip1 point
mutation knockin mice show enlarged postnatal leaflets as well as myxomatous adult
leaflets.
In order to determine the mechanism by which Dzip1 deletion results in MVP
further experiments are needed. Loss of Dzip1 in mouse models results in myxomatous
valve phenotype similar to the Ift88 conditional mice. Increases in ECM is seen in both
models. To further evaluate these changes RNA seq could be done at a time point prior to
valve enlargement, such as E13, to compare changes between Ift88 and Dzip1 conditional
mice. Further studies looking at hedgehog signaling may also prove valuable. Since
Dzip1 has been previously implicated in sequestering Gli3 in the cytoplasm but we see no
change in Gli3 processing IHC looking at Gli3 localization in conditional knockout mice
could be interesting.
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CHAPTER 5: OVERALL DISCUSSION
Valve disease is one of the most common cardiac diseases affecting between 0.52% of individuals. MVP and BAV are two of the most common valve diseases and
currently the only treatment option is surgical replacement or repair. The etiology of
these diseases are poorly understood however evidence has shown a developmental
origin. Better understanding of these developmental processes and signaling pathways
has provided insight into the mechanism by which primary cilia regulate ECM
production. Future work is still needed to identify which signaling pathway is responsible
for this regulation although some evidence suggests non-canonical hedgehog signaling is
playing a role.
Currently the only treatment option for both MVP and BAV is invasive surgery
to either repair or replace the damaged valve. For patients with BAV and aortic stenosis,
the gold standard of treatment is surgical aortic valve replacement (SAVR) which has
proven to be both symptomatic and provide survival benefits (Al Kindi, Salhab et al.
2014). Over the past decade these procedures have improved greatly and inventions such
as the MitraClip, a trans catheter mitral valve repair device designed to reduce MR, has
helped patients live longer healthier lives (Velazquez, Samad et al. 2015). However, there
is still room for improvements. Secondary complications caused by valve disease cause
damage to the heart in other ways resulting in long term cardiovascular disease and
current treatment options are often invasive, risky and not always suitable for the elderly
population most often effected by these diseases. Devices such as the MitraClip help
improve the 30-day mortality of 7.7% of MitraClip patients compared to what is
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predicted had mitral valve surgery been attempted. However, these devices are not
perfect. The Endovascular Valve Edge-to-Edge Repair Study (EVEREST II) study
showed mitral valve surgery was more effective in reducing MR than the MitraClip
(George, Varghese et al. 2011, Velazquez, Samad et al. 2015). For these reasons a better
understanding of the developmental origins and molecular mechanisms for these diseases
will allow clinicians to move forward with less invasive more effective treatment options.
Structural changes that occur in the valves of patients with MVP and BAV
include myxomatous degeneration. A myxomatous valve has increased accumulation of
proteoglycans, fragmented collagens, and hyperplasia. Over time, these changes in the
histoarchitecture of the valve result in mechanically weakened structure which become
elongated and, in the case of MVP, are susceptible to prolapse. Little is known about how
the valves become myxomatous although evidence points to a genetic origin.
Our studies suggest that primary cilia play a major role in this process. Through
spatial and temporal regulation of valve differentiation and matrix deposition, the primary
cilia act as molecular clocks. In this way the primary cilia relay information to the cell
telling it what stage in development the tissue is undergoing and allowing the cells to
differentiate producing the correct ratio of ECM at each stage of development. Loss of
this signal results in improper valve differentiation and matrix deposition. Structural
changes during development then progress to adult valve disease because the tissue is
compromised at an early age. Over the course of the patients life, enlarged postnatal
leaflets cause endothelial boarders to stretch and weaken which potentially allows for
cytokine release and infiltration of extracardiac cells. Previous models of myomatous
valve disease show infiltration of hematopoetic derived CD45 positive cells. This
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infiltration leads to increased MMP secretion and further matrix degradation. At this
stage in a patient’s life they may become symptomatic while early in life when the
disease is still occurring they would be considered non-symptomatic. For these reasons,
understanding the processes involved in mitral and aortic valve development are essential
in determining a molecular mechanism for valve disease.
In our studies we noticed the development of BAV in our Ift88 conditional
knockout mice but not in our Dzip1 conditional knockout mice. If both genes affect
primary cilia, how can this be the case? The severity of cilia loss may be an explanation.
Conditional deletion of Ift88 to remove primary cilia is the most severe level of cilia loss
while deletion of Dzip1 deletion is a less severe. Ift88 conditional knockout mice develop
both MVP and BAV while conditional heterozygous only develop MVP. In the Dzip1
conditional knockout mice we observed MVP but not BAV. The Ift88 conditional
knockout mice have almost complete cilia loss with a few very short cilia while the
Dzip1 conditional knockout mice have shorter cilia.
An additional explanation could be differences in tissue expression of the
molecules involved in Dzip1 signaling. The “ciliome” constitutes ~2-3% of all
mammalian genes and it’s likely that components of the ciliome are expressed in unique
spatial, temporal, and tissue-specific manners, such that the mitral and aortic valves differ
in presence/expression of subsets of cilia genes. It is possible that Dzip1 signaling is
more important for mitral valve development than aortic valve development. To test this
stains for various pathway members could be done in both mitral and aortic valves to see
if there was variation in expression. IHC showing differences for any of the Gli
transcription factors, members of the non-canonical HH pathway such as Rac and Rho, or
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PDGFRα signaling pathway such as AKT, or PI3K could explain differences in
phenotypes.
More work is needed to determine a signaling mechanism for these changes. In
both aortic and mitral valves, loss of primary cilia with conditional deletion of Ift88
resulted in increased ECM production and decreased cell density. Determining how loss
of primary cilia results in increased matrix proved to be complicated but we can speculate
about what pathways may be involved. Since loss of Dhh resulted in a valve phenotype
similar to that seen with deletion of Ift88 it is possible that the HH signaling pathway is
involved. No change was observed in processing of Gli3 which could mean that Gli2 is
playing a role or that Dhh is signaling in a non-canonical way. To further evaluate these
pathways multiple experiments could be done. Western blots using tissue from Dzip1 and
Ift88 conditional knockout and wild type tissue could be probed for PERK, pAKT, PI3K
or Gli transcription factors. To determine if non-canonical HH signaling is occurring a
Rac/Rho activity assay can be done. In this assay, Rac/Rho in its active form, bound to
GTP, is pulled down using a specific antibody. The protein is then eluted off the beads
and can be run in on a western blot to look at relative abundance.
From the data collected we propose the following working model. Inhibition of
ciliogenesis, reception of signal by the cilia, or deletion of ligand needed for cilia
signaling results in improper valve development ultimately leading to valve disease.
Disruption of cilia structure through deletion of Ift88 results in myxomatous mitral and
aortic valves with a high penetrance of BAV. These mice develop enlarged mitral valves
with increased expression of versican and collagen. A similar phenotype is observed in
the Dzip1 conditional knockouts. Conditional loss of Dzip1results in enlarged
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myxomatous mitral valves that ultimately results in MVP. Disruption of the HH ligand
Dhh also causes enlarged postnatal valves although the mechanism by which this is
occurring is still under investigation.
In the future this work has the potential to influence therapies for these diseases.
One common thread between multiple models of valve disease is the disruption of the
ECM boundaries. If a therapy could target this disruption we could potentially stop
further degradation of the matrix and maintain a functional valve leaflet. Therapies using
Nano particles are appealing for this function. Using antibody targeted against
fragmentation of collagen or elastin tethered to nanoparticles which are filled with drugs
we could possibly target the damaged tissue before further issues could arise. One
potential drug option would be something that repairs fragmented elastin or collagen.
Another potential option could be a crisper molecule that could repair the mutation that is
seen in the patients with the DZIP1 mutations.
More work is still needed to further elucidate the molecular mechanisms involved
in valve disease, however, substantial progress has been made. The concept of valve
disease as a ciliopathy is a novel idea and opens up the potential for further research
which is likely to help undercover the ethology of these diseases.

Here we present

genetic, cellular and molecular data to broadly support primary cilia defects as a cause of
MVP and BAV, which help to define the molecular and developmental basis for these
common diseases.
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CHAPTER 6: MATERIALS AND METHODS
Mouse Studies
All mouse experiments were performed under protocols previously approved by the
Institutional Animal Care and Use Committee (IACUC) at the Medical University of
South Carolina. Prior to cardiac resection, mice were euthanized in accordance with the
Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised
1996.) Comparisons between sexes were evaluated and no significant differences were
observed. As such, data is comprised of pooled sexes for all experiments. Mating
strategies were as follows. Female mice heterozygous for the conditional “floxed” allele
of each respective gene (Ift88, Dzip1, and Dhh) were bred with male transgenic mice
who were heterozygous for the conditional “floxed” allele as well as expressing Cre
under the control of the respective promoters (NfatC1, NfatC1- enhancer, Periostin, or
Tie2). Mice resulting from these mating would be Cre negative or positive and had the
potential to be wildtype, heterozygous or homozygous for the floxed allele. Filamin A
conditional mice were bred similarly but male mice were conditional knockouts as
FilaminA is X chromosome specific. Dchs1 global mice were generated using a
heterozygous female with a heterozygous male. All mice were outbred.

IFT88 conditional mice
Ift88 conditional mice and genotyping were previously described(Haycraft, Zhang et al.
2007). Histology was performed on embryonic and adult wild-type (NfatC1Cre-;Ift88f/f)
conditional heterozygous (NfatC1Cre-;Ift88f/+) and conditional knockout (NfatC1Cre+;Ift88f/f)

hearts on mixed background.
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Dzip1 conditional mice
Conditional knockout mice were generated by a targeted homologous recombination
approach using a Dzip1 targeting construct (PG00125_Z_2_E04) purchased from the
KOMP mouse repository. The conditional knockout would delete exons 8 and 9 (Dzip1202 transcript) and cause a reading frame shift and premature translational termination.
The conditional mutant allele was genotyped using forward primer: 5’GCCAAAGTGGTTTGCCTGACA -3’ and reverse primer: 5’GCAGGTTAAACACTCATATAGC-3’ (210bp for wt and 290bp for mutant). Histology
was performed on embryonic and adult wild-type (NfatC1Cre-;Dzip1+/+) conditional
heterozygous (NfatC1Cre+-:Dzip1f/+) and conditional knockout (NfatC1Cre+;Dzip1f/f) hearts
on mixed background. Additional wild-type (Tie2Cre+;Dzip1+/+) and conditional knockout
(Tie2Cre+;Dzip1f/f) adult hearts were examined as well. Data collected from the NfatC1
and Tie2 Cre lines were comparable.

Histology, Immunohistochimistry/Immunofluorescence
Embryonic and adult tissue were processed for hematoxylin and eosin (H and E) staining,
Herovici’s collagen stain and, immunohistochemistry/immunofluorescence (IHC) as
previously described. IHC of cilia stains to look at expression and measure cilia length
were done on 15 µm thick sections to insure measurement of full cilia length. Histology
and IHC were preformed using 5µm thick sections from E11,13,15,17, P0, and Adult (48month) aortic valves. H and E stains were performed as previously described. Herovci
stains were preformed using American MasterTech Herovici’s Collagen Stain Kit
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Procedure (cat#KTHER). For immunohistochemistry (IHC): Antigen retrieval was
performed for 1 minute using antigen unmasking solution (Vector Laboratories,
Burlingame, CA, USA, Cat#H-3300) by pressure cooker (Cuisinart, Stamford, CT,
USA). The following are the antibodies and their dilutions; Acetylated Tubulin (Sigma,
Cat#T6793, 1:500), Gamma Tubulin (Abcam, Cambridge, MA, USA, Cat#ab11317,
1:1000), Versican (gift from Stan Hoffman, Medical University of South Carolina, 1:
250), Collagen (gift from Stan Hoffman, Medical University of South Carolina, 1: 250),
MF20 (DSHB, Iowa City, IA, USA, Concentrate, I:50), Ki67 (Abcam, Cat#ab16667,
1:250), Phospho-histone H3 (EMD Milipore, Darmstadt Germany, Cat#06-570, 1:250),
Smoothened (LSBio, Seattle WA, Cat#LS-A2666, 1:250), Gli3 (Origene, Rockville MD,
Cat#TA337186, 1:250). Primary antibody was detected using fluorescent secondary
antibody, Goat anti-Mouse IgG Alexa fluro 488 (Cat#A-11029, 1:100), Goat anti-Rabbit
Alexa fluor 488 (Cat#A-11034, 1:100) anti-Mouse Alexa fluor 568 (Cat#A-11004,
1:100), anti-Rabbit Alexa fluor 568 (Cat#A-11036, 1:100) Cy5 goat anti-Mouse (Cat#A10524, 1:100) and Cy5 goat anti-Rabbit (Cat#A-10523, 1:100) (Life Technologies,
Rockville, MD, US). Nuclei were counterstained with Hoechst (Life Technologies, Cat
#H3569, 1:10,000) for 10 minutes and slides were coverslipped with SlowFade mounting
medium (Life Technologies, Cat#S36937). Fluorescence imaging was preformed using
Zeiss Axioimager M2 and Leica TCS SP5 AOBS Confocal Microscope System.

Confocal Microscopy
Images were acquired using the Leica TCS SP5 AOBS Confocal Microscope System (
Leica Microsystems, Inc., 410 Eagleview Boulevard, Suite 107, Exton, PA 19341). Z-
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stacks were set by finding the highest and lowest depth with visible fluorescence and
using the system optimized setting to determine steps. Z-stacks were then compiled to
form maximum projection images.

3D reconstruction
3D reconstructions of H and E images were preformed to generate volumetric
measurements of postnatal day 0 right, left, and non-coronary leaflets, similarly to
previous reports. Briefly, 5µm sections throughout the width of the aortic valve were H
and E stained and imaged using the Olympus BX40 bright field microscope. Images were
then aligned using ImageJ FIJI and imported into Imaris 8.0. Manual reconstruction was
performed by tracing each individual cusp on every section and combining all traces to
create a 3D structure. Additionally, 3D reconstructions of immunohistochemistry were
performed by importing Z-stack images of 15µm sections into Imaris and creating
surface renderings based on intensity of the stains.

Quantifications
Cilia length measurements were performed using Z-stack images of right coronary cusps
(Chapter 2) or posterior leaflets (Chapter 3 and 4) stained with acetylated alpha tubulin,
gamma tubulin and counterstained with Hoechst. Z-stack images were then imported into
Imaris software and measurements were taken from the base to the tip of the axoneme.
All cilia in the field of view were measured, n=3 per developmental time point or
genotype. Measurements were then ranked and grouped; zero microns represents absence
of cilia. Quantification of cilia length in versican and collagen regions was performed on
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left coronary leaflets in the same way, n=3. Average cilia length was then calculated and
Student’s t-test was done (p<0.001).
Cell density quantifications were measured by counting all nuclei in a specified area,
25.4mm2 for post-natal measurement and 22 mm2 for adult measurements. Postnatal
measurements were taken at the base and tip of the right coronary leaflets, n=3. Adult
measurements were taken at the tip of right coronary leaflets, n=3. Measurements were
compared to wild-type data to generate fold change and statistical significance was
calculated using a Student’s t-test (p<0.001).
Quantification of Collagen was preformed using Herovici stained right coronary leaflets.
Surface area of red staining was measured in Image J and percentages were calculated
based on total leaflet surface area. n=3, with three areas per animal measured.

RNA Seq analysis
Mitral leaflets were dissected from P0 NfatC1Cre(+); Ift88f/f and P0 NfatC1Cre(+), Ift88+/+.
Total RNA was isolated using MicroRNeasy (Qiagen). Purity and quantification was
determined by Bioanalyzer. The library preparation was made using the SMART-Seq®
v4 RNA-seq kit(Clontech Laboratories, Mountain View, CA) following the
manufacturer's instructions.
The analysis was carried out on an OnRamp Bioinformatics Genomics Research Platform
(OnRamp Bioinformatics, San Diego, CA). “OnRamp’s advanced Genomics Analysis
Engine utilized an automated RNAseq workflow to process the data, including (1) data
validation and quality control, (2) read alignment to the mouse genome (mm10) using
STAR RNA-seq aligner, (3) generation of gene-level count data with HTSeq, and (4)
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differential expression analysis with DEseq2, which enabled the inference of differential
signals with robust statistical power(Dobin, Davis et al. 2013, Love, Huber et al. 2014,
Davis-Turak, Courtney et al. 2017). Transcript count data from DESeq2 analysis of the
samples were sorted according to their adjusted p-value or q-value, which is the smallest
false discovery rate (FDR) at which a transcript is called significant. FDR is the expected
fraction of false positive tests among significant tests and was calculated using the
Benjamini-Hochberg multiple testing adjustment procedure(Benjamini and Hochberg
1995). The DE list was them submitted to the iPathway Guide tool from Advaita®
Bioinformatics, this tool uses a systems biology approach in order to identify pathways
that are significantly impacted in any condition - from high-throughput gene expression
data. The impact analysis incorporates the classical probabilistic component of the
magnitude of the expression changes of each gene, the position of the differentially
expressed genes on the given pathways, the topology of the pathway that describes how
these genes interact, and the type of signaling interactions between them(Draghici, Khatri
et al. 2007).

Echocardiography
Mice were anesthetized with 3–5% isoflurane vapor in an anesthesia chamber and then
placed on a biofeedback warming station with nose cone anesthesia of 1.5–2.5%
isoflurane, which was regulated to maintain a heart rate between 500 to 600 beats/min,
while providing anesthesia (abolition of the toe pinch reflex). The hair over the chest was
removed using a commercially available depilatory cream. Ultrasound gel was placed on
the chest, and echocardiography measurements were performed using a 40-MHz probe
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with a spatial resolution of 30 µm (Vevo2100; Visualsonics). Two-dimensional and Mmode echo images were obtained in the parasternal short- and long-axis views. LV
volumes and ejection fractions were computed from the parasternal long-axis recordings
and LV mass was computed from the short axis measurements (Mani, Balasubramanian
et al. 2009, Kholmukhamedov, Logdon et al. 2014, Zavadzkas, Stroud et al. 2014). For
terminal studies, heart harvest was performed following this procedure. The entire
echocardiography procedure took ∼20-30 min per mouse.

Human Studies
Fetal hearts (12 and 20 weeks) were obtained from elective terminations that were
lawfully performed at Brighman and Women’s Hospital, Boston, MA under IRB
approval (2010P001333). Samples were stored in RNA later and maintained at the
Harvard BioBank. Tissues were washed and refixed in formalin followed by tissue
processing, embedding and sectioning as we have previously described (Durst, Sauls et
al. 2015). MVP was diagnosed in two-dimensional long-axis echocardiographic views
by >2mm leaflet displacement superior to the annulus hinge points (Levine,
Stathogiannis et al. 1988, Levine, Handschumacher et al. 1989). Prodromal morphology
was noted based on leaflet coaptation abnormally displaced >40% anterior relative to the
mitral annulus, and minimal superior displacement was based on <2mm displacement
(Nesta, Leyne et al. 2005, Delling, Gona et al. 2014). These morphologies associate with
progressive prolapse (Delling, Rong et al. 2016)and link to the haplotype of affecteds
with fully diagnostic displacement (Nesta, Leyne et al. 2005).
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Genetic Studies:
Complete details on the family in Figure 3A and the original linkage analysis can be
found in (Nesta, Leyne et al. 2005). Epstein Barr Virus (EBV) transformed lymphoblast
cell lines were created on all members of the family available for study. Protein was
isolated from cultures for the individuals marked with a “*” in Figure 3A and Western
analysis performed using a DZIP1 rabbit monoclonal antibody (epitomics)

Sanger

sequencing using primers for each exon of DZIP1 was performed for all members of the
pedigree. Exome sequencing was performed on four individuals carrying the linked
haplotype and all genes in the candidate interval were analyzed for coding sequence
mutations.
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Family 2 Genetics:
PCR reactions & High-Resolution Melting (HRM) Analysis
PCR for HRM assay were performed in “LightCycler® 480 Multiwell Plate 96, white”
reaction plates. 12.5 ng of genomic DNA and 0.25µM final concentration of each primer
were used per reaction (10µL final volume).
Volume per well
Reagent

(µL)

Water, PCR Grade

2.5

Primer Forward (10µM)

0.25

Primer Reverse (10µM)

0.25

LightCycler® 480 Probes Master, 2x
concentrated

5

LightCycler® 480 ResoLight Dye, 20x
concentrated

0.75

DNA sample (10ng/µL) or Negative
control (Water)

1.25

The PCR and HRM assays were performed on the “LightCycler® 480 Instrument”
(Roche). Run and analysis are performed with the “LightCycler® 480 Software Version
1.5” and the “LightCycler® 480 Gene Scanning module” (Roche).
For “ResoLight Dye” detection, the filter “SYBR Green I / HRM Dye (465-510 nm)”
was selected (Integration Time Mode: Dynamic).
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Initial activation step was set at 95°C for 10min (Ramp rate 4.4°C/sec), followed by a 55cycle program [denaturation, 95°C for 15sec (Ramp rate 4.4°C/sec); annealing,
touchdown 68°C to 55°C (with 1°C step size and 1 cycle step delay) for 15sec (Ramp
rate 2.2°C/sec); and elongation, 72°C for 20sec (Ramp rate 4.4°C/sec); acquisition mode,
“Single”]. The subsequent melting program included three steps: denaturation at 95°C for
1 sec (Ramp rate 4.4°C/sec), renaturation at 40°C for 30sec (Ramp rate 2.2°C/sec), and
then melting from 65°C to 97°C (Ramp rate 2.2°C/sec) with 25 acquisitions per °C
(Ramp rate 0.02°C/sec); acquisition mode, “Continuous”) and a final cooling step was set
at 50°C for 30sec (Ramp rate 2.2°C/sec). Finally, after the run analysis, real-time PCR
products were directly sequenced in order to obtain the clusters genotype (few samples
from each curve cluster). Sanger sequencing was performed on the same PCR amplicons
and primers, using standard conditions.
Genome wide association (GWAS) study on Cilia
Using our previous GWAS on MVP (Dina, Bouatia-Naji et al. 2015), we tested for a
global enrichment for significant association among a large list including 278 different
genes reported as involved in cilia biology, mainly as harboring rare mutations in a
diverse panel of ciliopathies. We used the SNP test ratio method as described in
(O'Dushlaine, Kenny et al. 2009). In this analysis we first performed several GWAS
where phenotypes of cases and controls were permuted to generate 1000 simulated
GWAS. Then, according to a pre-defined p-value threshold, the method consists in
counting the number of times the pathway tested included a higher ratio of significant to
non significant SNPs, compared to the 1000 simulated GWAS. As recommended for this
method, we used the KEGG pathways catalog, in addition to our customized list of cilia
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genes. Given the limited number of highly associated SNPs in the current GWAS that
includes ∼1500 cases and 2500 controls, we set significance at P<0.05 to allow more
SNPs to contribute the analyses. Among nominally associated SNPs in the GWAS
(SNPs<0.05), we found that SNPs that map in the cilia genes list are more likely to be
associated with MVP (P=0.03).

Statistics
Statistical significance was determined using a student’s t-test (two tailed, type 2) with
significance (p<0.05). Statistical data are presented as standard deviations from the mean.
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